<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        445-212-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        RESEDRA 1MG/ML ORAL SOLUTION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        RISPERIDONE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Oral solution
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        170.75
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SPIMACO" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO ADDWAEIH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N05AX08 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Resedra belongs to a group of medicines called &lsquo;anti-psychotics&rsquo;.</p><p>&nbsp;</p><p>Resedra is used to treat the following:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Schizophrenia, where you may see, hear or feel things that are not there, believe things that are nottrue or feel unusually suspicious, or confused</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mania, where you may feel very excited, elated, agitated, enthusiastic or hyperactive. Mania occurs inan illness called &ldquo;bipolar disorder&rdquo;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Short-term treatment (up to 6 weeks) of long-term aggression in people with Alzheimer&rsquo;s dementia,who harm themselves or others. Alternative (non-drug) treatments should have been used previously</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Short-term treatment (up to 6 weeks) of long-term aggression in intellectually disabled children (atleast 5 years of age) and adolescents with conduct disorder.</p><p>&bull; RESEDRA is indicated for the treatment of irritability associated with autistic disorder in<br />children and adolescents aged 5 to 16 years, including symptoms of aggression<br />towards others, deliberate self-injuriousness, temper tantrums, and quickly changing<br />moods.</p><p>Resedra can help alleviate the symptoms of your disease and stop your symptoms from comingback.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Resedra:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic to risperidone or any of the other ingredients of this medicine (listed in section 6).</p><p>&nbsp;</p><p>If you are not sure if the above applies to you, talk to your doctor or pharmacist before using Resedra.</p><p><strong>&nbsp;</strong></p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before taking Resedra if:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have a heart problem. Examples include an irregular heart rhythm or if you are prone to lowblood pressure or if you are using medicines for your blood pressure. Resedra may cause low bloodpressure. Your dose may need to be adjusted</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You know of any factors which would favour you having a stroke, such as high blood pressure,cardiovascular disorder or blood vessel problems in the brain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have ever experienced involuntary movements of the tongue, mouth and face</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have ever had a condition whose symptoms include high temperature, muscle stiffness, sweatingor a lowered level of consciousness (also known as Neuroleptic Malignant Syndrome)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have Parkinson&rsquo;s disease or dementia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You know that you have had low levels of white blood cells in the past (which may or may not havebeen caused by other medicines)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are diabetic</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have epilepsy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are a man and you have ever had a prolonged or painful erection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have problems controlling your body temperature or overheating</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have kidney problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have liver problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have an abnormally high level of the hormone prolactin in your blood or if you have a possibleprolactin-dependent tumour.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You or someone else in your family has a history of blood clots, as antipsychotics have beenassociated with formation of blood clots.</p><p>&nbsp;</p><p>If you are not sure if any of the above applies to you, talk to your doctor or pharmacist before usingResedra.</p><p>&nbsp;</p><p>As dangerously low numbers of a certain type of white blood cell needed to fight infection in your blood hasbeen seen very rarely with patients taking Resedra, your doctor may check your white blood cell counts.</p><p>&nbsp;</p><p>Resedra may cause you to gain weight. Significant weight gain may adversely affect your health. Yourdoctor should regularly measure your body weight.</p><p>&nbsp;</p><p>As diabetes mellitus or worsening of pre-existing diabetes mellitus have been seen with patients takingResedra, your doctor should check for signs of high blood sugar. In patients with pre-existing diabetesmellitus blood glucose should be monitored regularly.</p><p>Resedra commonly raises levels of a hormone called &quot;prolactin&quot;. This may cause side effects such asmenstrual disorders or fertility problems in women, breast swelling in men (see Possible side effects). If suchside effects occur, evaluation of the prolactin level in the blood is recommended.</p><p>&nbsp;</p><p>During an operation on the eye for cloudiness of the lens (cataract), the pupil (the black circle in the middleof your eye) may not increase in size as needed. Also, the iris (the coloured part of the eye) may becomefloppy during surgery and that may lead to eye damage. If you are planning to have an operation on youreye, make sure you tell your eye doctor that you are taking this medicine.</p><p>&nbsp;</p><p><strong>Elderly people with dementia</strong></p><p>In elderly patients with dementia, there is an increased risk of stroke. You should not take risperidone if youhave dementia caused by stroke.</p><p>During treatment with risperidone you should frequently see your doctor.</p><p>Medical treatment should be sought straight away if you or your care-giver notice a sudden change in yourmental state or sudden weakness or numbness of your face, arms or legs, especially on one side, or slurredspeech, even for a short period of time. These may be signs of a stroke.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>Before treatment is started for conduct disorder, other causes of aggressive behaviour should have been ruledout.</p><p>If during treatment with risperidone tiredness occurs, a change in the time of administration might improveattention difficulties.</p><p>Before treatment is started your, or your child&rsquo;s body weight may be measured and it may be regularlymonitored during treatment.</p><p>A small and inconclusive study has reported an increase in height in children who took risperidone, butwhether this is an effect of the drug or due to some other reason is not known.</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and Resedra</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p><strong>&nbsp;</strong></p><p><strong>It is especially important to talk to your doctor or pharmacist if you are taking any of the following:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines that work on your brain such as to help you calm down (benzodiazepines) or somemedicines for pain (opiates), medicines for allergy (some antihistamines), as risperidone may increasethe sedative effect of all of these</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines that may change the electrical activity of your heart, such as medicines for malaria, heartrhythm problems, allergies (anti-histamines), some antidepressants or other medicines for mentalproblems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines that cause a slow heart beat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines that cause low blood potassium (such as certain diuretics)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines to treat raised blood pressure. Resedra can lower blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines for Parkinson&#39;s disease (such as levodopa)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Water tablets (diuretics) used for heart problems or swelling of parts of your body due to a build up oftoo much fluid (such as furosemide or chlorothiazide). Resedra taken by itself or with furosemide,may have an increased risk of stroke or death in elderly people with dementia.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines that increase the activity of the central nervous system (psychostimulants, such as methylphenidate).</p><p><strong>&nbsp;</strong></p><p><strong>The following medicines may reduce the effect of risperidone</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rifampicin (a medicine for treating some infections)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Carbamazepine, phenytoin (medicines for epilepsy)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Phenobarbital</p><p>If you start or stop taking such medicines you may need a different dose of risperidone.</p><p><strong>&nbsp;</strong></p><p><strong>The following medicines may increase the effect of risperidone</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Quinidine (used for certain types of heart disease)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Antidepressants such as paroxetine, fluoxetine, tricyclic antidepressants</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines known as beta blockers (used to treat high blood pressure)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Phenothiazines (such as medicines used to treat psychosis or to calm down)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cimetidine, ranitidine (blockers of the acidity of stomach)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itraconazole and ketoconazole (medicines for treating fungal infections)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Certain medicines used in the treatment of HIV/AIDS, such as ritonavir</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Verapamil, a medicine used to treat high blood pressure and/or abnormal heart rhythm.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sertraline and fluvoxamine, medicines used to treat depression and other psychiatric disorders.</p><p>If you start or stop taking such medicines you may need a different dose of risperidone.</p><p>&nbsp;</p><p>If you are not sure if any of the above applies to you, talk to your doctor or pharmacist before usingResedra.</p><p><strong>&nbsp;</strong></p><p><strong>Resedra with food, drink and alcohol</strong></p><p>You can take this medicine with or without food. You should avoid drinking alcohol when taking Resedra.</p><p><strong>&nbsp;</strong></p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, askyour doctor or pharmacist for advice before taking this medicine. Your doctor will decide if you cantake it</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The following symptoms may occur in newborn babies, of mothers that have used Resedra in the lasttrimester (last three months of their pregnancy): shaking, muscle stiffness, and/or weakness,sleepiness, agitation, breathing problems, and difficulty in feeding. If your baby develops any of thesesymptoms you may need to contact your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Resedra can raise your levels of a hormone called &quot;prolactin&quot; that may impact fertility (see Possibleside effects).</p><p><strong>&nbsp;</strong></p><p><strong>Driving and using machines</strong></p><p>Dizziness, tiredness, and vision problems may occur during treatment with Resedra. Do not drive or useany tools or machines without talking to your doctor first.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if youare not sure.</p><p><strong>&nbsp;</strong></p><p><strong>The recommended dose is as follows:</strong></p><p><strong>&nbsp;</strong></p><p><strong>For the treatment of schizophrenia</strong></p><p><strong>&nbsp;</strong></p><p><strong>Adults</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The usual starting dose is 2 mg per day, this may be increased to 4 mg per day on the second day</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your dose may then be adjusted by your doctor depending on how you respond to the treatment</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Most people feel better with daily doses of 4 to 6 mg</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This total daily dose can be divided into either one or two doses a day. Your doctor will tell you whichis the best for you.</p><p><strong>&nbsp;</strong></p><p><strong>Elderly people</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your starting dose will normally be 0.5 mg twice a day</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your dose may then be gradually increased by your doctor to 1 mg to 2 mg twice a day</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will tell you which is the best for you.</p><p><strong>&nbsp;</strong></p><p><strong>For the treatment of mania</strong></p><p><strong>&nbsp;</strong></p><p><strong>Adults</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your starting dose will usually be 2 mg once a day</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your dose may then be gradually adjusted by your doctor depending on how you respond to thetreatment</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Most people feel better with doses of 1 to 6 mg once a day.</p><p><strong>&nbsp;</strong></p><p><strong>Elderly people</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your starting dose will usually be 0.5 mg twice a day</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your dose may then be gradually adjusted by your doctor to 1 mg to 2 mg twice a day depending onhow much you respond to the treatment.</p><p><strong>&nbsp;</strong></p><p><strong>For the treatment of long-standing aggression in people with Alzheimer&rsquo;s dementia</strong></p><p><strong>&nbsp;</strong></p><p><strong>Adults (including elderly people)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your starting dose will normally be 0.25 mg twice a day</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your dose may then be gradually adjusted by your doctor depending on how you respond to thetreatment</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Most people feel better with 0.5 mg twice a day. Some patients may need 1 mg twice a day</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment duration in patients with Alzheimer&rsquo;s dementia should be not more than 6 weeks.</p><p><strong>&nbsp;</strong></p><p><strong>Use in children and adolescents</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Children and adolescents under 18 years old should not be treated with Resedra for schizophrenia ormania.</p><p><strong>&nbsp;</strong></p><p><strong>For the treatment of conduct disorder</strong></p><p>&nbsp;</p><p>The dose will depend on your child&rsquo;s weight:</p><p>For children who weigh less than 50 kg</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The starting dose will normally be 0.25 mg once a day</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The dose may be increased every other day in steps of 0.25 mg per day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The usual maintenance dose is 0.25 mg to 0.75 mg once a day.</p><p>&nbsp;</p><p>For children who weigh 50 kg or more</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The starting dose will normally be 0.5 mg once a day</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The dose may be increased every other day in steps of 0.5 mg per day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The usual maintenance dose is 0.5 mg to 1.5 mg once a day.</p><p>&nbsp;</p><p>Treatment duration in patients with conduct disorder should be not more than 6 weeks.</p><p>&nbsp;</p><p>Children under 5 years old should not be treated with Resedra for conduct disorder.</p><p>&nbsp;Irritability Associated with Autistic Disorder &ndash; Pediatrics (Children and<br />Adolescents) :<br />The dosage of RESEDRA should be individualized according to the response and tolerability<br />of the patient. The total daily dose of RESEDRA can be administered once daily, or half the<br />total daily dose can be administered twice daily.<br />For patients with body weight less than 20 kg, initiate dosing at 0.25 mg per day. For patients<br />with body weight greater than or equal to 20 kg, initiate dosing at 0.5 mg per day. After a<br />minimum of four days, the dose may be increased to the recommended dose of 0.5 mg per day<br />for patients less than 20 kg and 1.0 mg per day for patients greater than or equal to 20 kg.<br />Maintain this dose for a minimum of 14 days. In patients not achieving sufficient clinical</p><p>response, the dose may be increased at intervals of 2 weeks or greater, in increments of 0.25 mg<br />per day for patients less than 20 kg, or increments of 0.5 mg per day for patients greater than or<br />equal to 20 kg. The effective dose range is 0.5 mg to 3 mg per day. No dosing data are available<br />for children who weigh less than 15 kg.<br />Once sufficient clinical response has been achieved and maintained, consider gradually lowering<br />the dose to achieve the optimal balance of efficacy and safety. The physician who elects to use<br />RESEDRA for extended periods should periodically re-evaluate the long-term risks and<br />benefits of the drug for the individual patient.<br />Patients experiencing persistent somnolence may benefit from a once-daily dose administered at<br />bedtime or administering half the daily dose twice daily, or a reduction of the dose.</p><p>&nbsp;</p><p>People with kidney or liver problems</p><p>Regardless of the disease to be treated, all starting doses and following doses of risperidone should behalved. Dose increases should be slower in these patients.</p><p>Risperidone should be used with caution in this patient group.</p><p><strong>&nbsp;</strong></p><p><strong>Method of administration</strong></p><p>&nbsp;</p><p>For oral use.</p><p><strong>&nbsp;</strong></p><p><strong>Resedra oral solution</strong></p><p>The solution comes with a syringe. This should be used to help you measure the exact amount ofmedicine you need.</p><p>Follow these steps:</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Remove the child-proof cap. Push the plastic screw cap down while turning it counter clockwise(Figure 1)</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Insert the syringe into the bottle</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; While holding the bottom ring, pull the top ring up to the mark that corresponds to the number ofmillilitres or mg you need to take (Figure 2)</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Holding the bottom ring, remove the entire syringe from the bottle (Figure 3)</p><p>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Empty the syringe into any non-alcoholic drink, except for tea. Slide the upper ring down</p><p>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Close the bottle</p><p>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rinse the syringe with some water.</p><p><img alt="" width="352" height="449" src="data:image/png;base64,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" /></p><p>&nbsp;</p><p><strong>If you take more Resedra than you should</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; See a doctor right away. Take the medicine pack with you</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In case of overdose you may feel sleepy or tired, or have abnormal body movements, problemsstanding and walking, feel dizzy due to low blood pressure, or have abnormal heartbeats or fits.</p><p><strong>&nbsp;</strong></p><p><strong>If you forget to take Resedra</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you forget to take a dose, take it as soon as you remember it. However, if it is almost time for yournext dose, skip the missed dose and continue as usual. If you miss two or more doses, contact yourdoctor</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Do not take a double dose (two doses at the same time) to make up for a forgotten dose</strong></p><p><strong>&nbsp;</strong></p><p><strong>If you stop taking Resedra</strong></p><p>You should not stop taking this medicine unless told to do so by your doctor. Your symptoms may return. Ifyour doctor decides to stop this medicine, your dose may be decreased gradually over a few days.</p><p>&nbsp;</p><p><strong>Resedra oral solution contains benzoic acid.</strong></p><p><strong>&nbsp;</strong></p><p>This medicine contains 2 mg benzoic acid in each 1 ml of oral solution. Benzoic acid may increase jaundice (yellowing of the skin and eyes) in newborn babies (up to 4 weeks old).</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Tell your doctor immediately if you:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Experience blood clots in the veins, especially in the legs (symptoms include swelling, pain, andredness in the leg), which may travel through blood vessels to the lungs causing chest pain anddifficulty breathing. If you notice any of these symptoms seek medical advice immediately</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Have dementia and experience a sudden change in your mental state or sudden weakness or numbnessof your face, arms or legs, especially on one side, or slurred speech, even for a short period of time.These may be signs of a stroke</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Experience fever, muscle stiffness, sweating or a lowered level of consciousness (a disorder called&ldquo;Neuroleptic Malignant Syndrome&rdquo;). Immediate medical treatment may be needed</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Are a man and experience prolonged or painful erection. This is called priapism. Immediate medicaltreatment may be needed</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Experience involuntary rhythmic movements of the tongue, mouth and face. Withdrawal of risperidonemay be needed</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Experience severe allergic reaction characterised by fever, swollen mouth, face, lip or tongue,shortness of breath, itching, skin rash or drop in blood pressure.</p><p>&nbsp;</p><p>The following side effects may happen:</p><p><strong>&nbsp;</strong></p><p><strong>Very Common (may affect more than 1 in 10 people):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty falling or staying asleep</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Parkinsonism: This condition may include: slow or impaired movement, sensation of stiffness ortightness of the muscles (making your movements jerky), and sometimes even a sensation ofmovement &quot;freezing up&quot; and then restarting. Other signs ofparkinsonism include a slow shufflingwalk, a tremor while at rest, increased saliva and/or drooling, and a loss of expression on the face.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling sleepy, or less alert</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache.</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Common (may affect up to 1 in 10 people):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pneumonia, Infection of the chest (bronchitis), Common cold symptoms, Sinus infection, Urinary tractinfection, Ear infection, Feeling like you have the flu</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Raised levels of a hormone called &quot;prolactin&quot; found in a blood test (which may or may not causesymptoms). Symptoms of high prolactin occur uncommonly and may include in men breast swelling,difficulty in getting or maintaining erections, decreased sexual desire or other sexual dysfunction. Inwomen they may include breast discomfort, leakage of milk from the breasts, missed menstrualperiods, or other problems with your cycle or fertility problems.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weight gain, Increased appetite, Decreased appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sleep disorder, Irritability, Depression, Anxiety, Restlessness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dystonia: This is a condition involving slow or sustained involuntary contraction of muscles. While itcan involve any part of the body (and may result in abnormal posture), dystonia often involvesmuscles of the face, including abnormal movements of the eyes, mouth, tongue or jaw.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dyskinesia: This is a condition involving involuntary muscle movements, and can include repetitive,spastic or writhing movements, or twitching.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tremor (shaking)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blurry vision, Eye infection or &quot;pink eye&quot;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rapid heart rate, High blood pressure, Shortness of breath</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sore throat, Cough, Nosebleeds, Stuffy nose</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abdominal pain, Abdominal discomfort, Vomiting, Nausea, Constipation, Diarrhea, Indigestion, Drymouth, Toothache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash, Skin redness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle spasms, Bone or muscle ache, Back pain, Joint pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Incontinence (lack of control) of urine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling of the body, arms or legs, Fever, Chest pain, Weakness, Fatigue (tiredness), Pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fall.</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Uncommon (may affect up to 1 in 100 people):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infection of the breathing passages, Bladder infection, Eye infection, Tonsillitis, Fungal infection ofthe nails, Infection of the skin, An infection confined to a single area of skin or part of the body, Viralinfection, Skin inflammation caused by mites</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decrease in the type of white blood cells that help to protect you against infection, White blood cellcount decreased, Decrease in platelets (blood cells that help you stop bleeding), Anemia, Decrease inred blood cells, Increase in eosinophils (a type of white blood cell) in your blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reaction</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diabetes or worsening of diabetes, High blood sugar, Excessive drinking of water</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weight loss, Loss of appetite resulting in malnutrition and low body weight</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased cholesterol in your blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Elated mood (mania), Confusion, Decreased sexual drive, Nervousness, Nightmares</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tardive dyskinesia (twitching or jerking movements that you cannot control in your face, tongue, orother parts of your body). Tell your doctor immediately if you experience involuntary rhythmicmovements of the tongue, mouth and face. Withdrawal of Resedra may be needed</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sudden loss of blood supply to brain (stroke or &quot;mini&quot; stroke)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Unresponsive to stimuli, Loss of consciousness, Low level of consciousness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Convulsion (fits), Fainting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A restless urge to move parts of your body, Balance disorder, Abnormal coordination, Dizziness uponstanding, Disturbance in attention, Problems with speech, Loss or abnormal sense of taste, Reducedsensation of skin to pain and touch, A sensation of tingling, pricking, or numbness skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oversensitivity of the eyes to light, Dry eye, Increased tears, Redness of the eyes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sensation of spinning (vertigo), Ringing in the ears, Ear pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Atrial fibrillation (an abnormal heart rhythm), An interruption in conduction between the upper andlower parts of the heart, Abnormal electrical conduction of the heart, Prolongation of the QT intervalfrom your heart, Slow heart rate, Abnormal electrical tracing of the heart (electrocardiogram or ECG),A fluttering or pounding feeling in your chest (palpitations)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low blood pressure, Low blood pressure upon standing (consequently, some people takingResedra may feel faint, dizzy, or may pass out when they stand up or sit up suddenly, Flushing)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pneumonia caused by inhaling food, Lung congestion, Congestion of breathing passages, Crackly lungsounds, Wheezing, Voice disorder, Breathing passage disorder</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stomach or intestinal infection, Stool incontinence, Very hard stool, Difficulty swallowing, Excessivepassing of gas or wind</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hives (or &quot;nettle rash&quot;), Itching, Hair loss, Thickening of skin, Eczema, Dry skin, Skin discoloration,Acne, Flaky, itchy scalp or skin, Skin disorder, Skin lesion</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An increase of CPK (creatine phosphokinase) in your blood, an enzyme which is sometimes releasedwith muscle breakdown</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal posture, Joint stiffness, Joint swelling, Muscle weakness, Neck pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Frequent passing of urine, Inability to pass urine, Pain when passing urine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Erectile dysfunction, Ejaculation disorder</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loss of menstrual periods, Missed menstrual periods or other problems with your cycle (females)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Development of breasts in men, Leakage of milk from the breasts, Sexual dysfunction, Breast pain,Breast discomfort, Vaginal discharge</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling of the face, mouth, eyes, or lips</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chills, An increase in body temperature</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A change in the way you walk</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling thirsty, Feeling unwell, Chest discomfort, Feeling &quot;out of sorts&quot;, Discomfort</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased liver transaminases in your blood, Increased GGT (a liver enzyme called gammaglutamyltransferase)in your blood, Increased liver enzymes in your blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Procedural pain.</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Rare (may affect up to 1 in 1,000 people):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inappropriate secretion of a hormone that controls urine volume</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sugar in the urine, Low blood sugar, High blood triglycerides (a fat)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lack of emotion, Inability to reach orgasm</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Neuroleptic malignant syndrome (confusion, reduced or loss of consciousness, high fever, severe muscle stiffness, and sweating)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood vessel problems in the brain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Coma due to uncontrolled diabetes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shaking of the head</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Glaucoma (increased pressure within the eyeball), Problems with movement of your eyes, Eye rolling,Eyelid margin crusting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Eye problems during cataract surgery. During cataract surgery, a condition called intraoperative floppyiris syndrome (IFIS) can happen if you take or have taken Resedra. If you need to have cataractsurgery, be sure to tell your eye doctor if you take or have taken this medicine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dangerously low numbers of a certain type of white blood cell needed to fight infection in your blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe allergic reaction characterised by fever, swollen mouth, face, lip or tongue, shortness of breath,itching, skin rash and sometimes drop in blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dangerously excessive intake of water</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Irregular heart beat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood clot in the legs, Blood clot in the lungs</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Trouble breathing during sleep (sleep apnea), Fast, shallow breathing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the pancreas, A blockage in the bowels</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swollen tongue, Chapped lips, Rash on skin related to drug</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dandruff</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Breakdown of muscle fibers and pain in muscles (rhabdomyolysis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A delay in menstrual periods, Enlargement of the glands in your breasts, Breast enlargement,Discharge from the breasts</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased insulin (a hormone that controls blood sugar levels) in your blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Priapism (a prolonged penile erection that may require surgical treatment)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hardening of the skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased body temperature, Coldness in arms and legs</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Symptoms of drug withdrawal</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Yellowing of the skin and the eyes (jaundice).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sleep walking</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sleep-related eating disorder</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Not moving or responding while awake (catatonia).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dangerously excessive intake of water</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Very rare (may affect up to 1 in 10,000 people):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Life threatening complications of uncontrolled diabetes.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Serious allergic reaction with swelling that may involve the throat and lead to difficulty breathing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lack of bowel muscle movement that causes blockage.</p><p>&nbsp;</p><p>&nbsp;</p><p>The following side effect has been seen with the use of another medicine called paliperidone that is verysimilar to risperidone, so these can also be expected with RESEDRA: Rapid heartbeat upon standing.</p><p>&nbsp;</p><p><strong>Additional side effects in children and adolescents</strong></p><p>&nbsp;</p><p>In general, side effects in children are expected to be similar to those in adults.</p><p>The following side effects were reported more often in children and adolescents (5 to 17 years) than inadults: feeling sleepy, or less alert, fatigue (tiredness), headache, increased appetite, vomiting, common coldsymptoms, nasal congestion, abdominal pain, dizziness, cough, fever, tremor (shaking), diarrhoea, andincontinence (lack of control) of urine.</p><p><strong>&nbsp;</strong></p><p><strong>Reporting of side effects</strong></p><p>&nbsp;</p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via The National Pharmacovigilance and Drug Safety Centre (NPC). By reporting side affects you can help provide more information on the safety of this medicine.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton, or bottle. The expiry date refers to the last day of that month.</p><p>Do not store above 30&deg;C.</p><p>Do not refrigerate or freeze.</p><p>&nbsp;</p><p>Once the bottle is opened, any unused portion of RESEDRA oral solution should be discarded after 3 months.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throwaway medicines you no longer use. These measures will help protect the environment.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is risperidone</p><p>Each 1 ml oral solution contains 1 mg risperidone.</p><p>&nbsp;</p><p>The other ingredients are:</p><p>Tartaric acid, Benzoic acid, Sodium hydroxide BP, Purified water BP.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Resedra oral solution is supplied in an amber glass bottle with a child-resistant plastic screw cap (CRC)and tamper-evident ring containing 100ml of a colourless solution, free from foreign matter. 

The 100 ml glass bottle of Resedra  is packed in a cardboard box containing a 3 ml oral syringe graduated with minimum 0.25 ml and a maximum of 3ml, graduation marks in 0.25 ml (equals 0.25 mg oral solution) increments up to 3 ml (equals 3 mg oral solution) are printed on the syringe and an adaptor for the syringe.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>SPIMACO</strong></p><p>Al-Qassim Pharmaceutical Plant</p><p>Saudi Pharmaceutical Industries &amp;</p><p>Medical Appliances Corporation.</p><p>Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                July 2021.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ينتمي&nbsp;ريسيدرا&nbsp;إلى&nbsp;مجموعة&nbsp;من&nbsp;الأدوية&nbsp;تسمى&nbsp;&#39;الأدوية المضادة&nbsp;للذهان&#39;.&nbsp;</p><p dir="RTL">يستخدم&nbsp;ريسيدرا&nbsp;لعلاج&nbsp;ما&nbsp;يلي:&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفصام،&nbsp;حيث&nbsp;قد&nbsp;ترى،&nbsp;تسمع&nbsp;أو&nbsp;تشعر بأشياء&nbsp;ليست&nbsp;موجودة،&nbsp;أو تعتقد&nbsp;في أشياء غير صحيحة أو تشعر&nbsp;على&nbsp;نحو&nbsp;غير&nbsp;طبيعي بالشك،&nbsp;أو&nbsp;الارتباك.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هوس،&nbsp;حيث&nbsp;قد&nbsp;تشعر&nbsp;باثارة&nbsp;شديدة،&nbsp;وابتهاج،&nbsp;وانفعال،&nbsp;وحماسة&nbsp;أو&nbsp;فرط&nbsp;في&nbsp;النشاط.&nbsp;يظهر الهوس&nbsp;في&nbsp;مرض&nbsp;يسمى&nbsp;&quot;اضطراب&nbsp;ثنائي&nbsp;القطب&quot;.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علاج&nbsp;قصير&nbsp;الأجل&nbsp;(لمدة&nbsp;تصل&nbsp;إلى&nbsp;6&nbsp;أسابيع)&nbsp;من&nbsp;العدوانية&nbsp;طويلة&nbsp;الأجل&nbsp;لدى&nbsp;المصابين&nbsp;بخرف&nbsp;الزهايمر،&nbsp;الذين&nbsp;يضرون&nbsp;أنفسهم&nbsp;أو&nbsp;غيرهم.&nbsp;وكانت تستخدم طرق علاجية&nbsp;بديلة&nbsp;(غير&nbsp;دوائية)&nbsp;سابقا.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العلاج&nbsp;قصير&nbsp;الأجل&nbsp;(حتى&nbsp;6&nbsp;أسابيع)&nbsp;من&nbsp;العدوانية&nbsp;طويلة&nbsp;الأمد&nbsp;في&nbsp;الأطفال&nbsp;المعاقين ذهنيا&nbsp;(البالغين&nbsp;5&nbsp;سنوات&nbsp;من&nbsp;العمر&nbsp;علي الأقل)&nbsp;والمراهقين&nbsp;الذين&nbsp;يعانون&nbsp;من&nbsp;اضطراب&nbsp;السلوك.&nbsp;</p><p dir="RTL">&bull; یستعمل ریسیدرا لعلاج التھیج المرتبط باضطراب التوحد لدى الأطفال والمراھقین الذین تتراوح أعمارھم بین 5 إلى<br />16 سنة، بما في ذلك أعراض العدوانیة تجاه الآخرین ، وإیذاء النفس المتعمد ، ونوبات الغضب ، والتغیر السریع في<br />الحالة المزاجیة .</p><p dir="RTL">&nbsp;</p><p dir="RTL">ريسيدرا&nbsp;يمكن&nbsp;أن&nbsp;يساعد&nbsp;في&nbsp;تخفيف&nbsp;أعراض&nbsp;مرضك&nbsp;ومنع عودة الأعراض مرة أخري.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا&nbsp;تتناول&nbsp;ريسيدرا:</strong>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا&nbsp;كنت&nbsp;تعاني&nbsp;من&nbsp;حساسية&nbsp;من&nbsp;ريسبيريدون&nbsp;أو&nbsp;أي&nbsp;من&nbsp;المكونات&nbsp;الأخرى&nbsp;لهذا&nbsp;الدواء&nbsp;(المدرجة&nbsp;في&nbsp;الفقرة&nbsp;6)&nbsp;.&nbsp;</p><p dir="RTL">إذا&nbsp;لم&nbsp;تكن&nbsp;متأكدا&nbsp;مما&nbsp;إذا&nbsp;كان&nbsp;ما&nbsp;سبق&nbsp;ينطبق&nbsp;عليك،&nbsp;تحدث&nbsp;مع&nbsp;طبيبك&nbsp;أو&nbsp;الصيدلي&nbsp;قبل&nbsp;استخدام&nbsp;ريسيدرا.&nbsp;</p><p dir="RTL"><strong>التحذيرات&nbsp;والاحتياطات</strong>&nbsp;</p><p dir="RTL">تحدث&nbsp;مع&nbsp;طبيبك&nbsp;أو&nbsp;الصيدلي&nbsp;قبل&nbsp;تناول&nbsp;ريسيدرا&nbsp;إذا:&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كانت&nbsp;لديك&nbsp;مشكلة&nbsp;في&nbsp;القلب.&nbsp;ومن&nbsp;الأمثلة&nbsp;على&nbsp;ذلك&nbsp;عدم&nbsp;انتظام&nbsp;ضربات&nbsp;القلب&nbsp;أو&nbsp;إذا&nbsp;كنت&nbsp;عرضة&nbsp;لانخفاض&nbsp;ضغط&nbsp;الدم&nbsp;أو&nbsp;إذا&nbsp;كنت&nbsp;تستخدم&nbsp;أدوية&nbsp;لعلاج&nbsp;ضغط&nbsp;الدم.&nbsp;قد يسبب&nbsp;ريسيدرا&nbsp;انخفاض&nbsp;ضغط&nbsp;الدم.&nbsp;وقد&nbsp;تحتاج&nbsp;إلى&nbsp;تعديل&nbsp;الجرعة.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت&nbsp;تعرف&nbsp;أي&nbsp;من&nbsp;العوامل&nbsp;التي&nbsp;من&nbsp;شأنها&nbsp;أن&nbsp;تزيد فرصة حدوث&nbsp;سكتة&nbsp;دماغية&nbsp;لديك،&nbsp;مثل&nbsp;ارتفاع&nbsp;ضغط&nbsp;الدم،&nbsp;واضطرابات&nbsp;القلب&nbsp;والأوعية&nbsp;الدموية&nbsp;أو&nbsp;مشاكل&nbsp;الأوعية&nbsp;الدموية&nbsp;في&nbsp;المخ.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت&nbsp;قد&nbsp;تعرضت في&nbsp;أي&nbsp;وقت&nbsp;مضى&nbsp;لحركات&nbsp;لا&nbsp;إرادية&nbsp;من&nbsp;اللسان&nbsp;والفم&nbsp;والوجه.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ظهرت عليك في&nbsp;أي&nbsp;وقت&nbsp;مضى&nbsp;حالة&nbsp;تشمل&nbsp;أعراض&nbsp;ارتفاع&nbsp;درجة&nbsp;الحرارة،&nbsp;وصلابة&nbsp;العضلات،&nbsp;والتعرق&nbsp;أو&nbsp;انخفاض&nbsp;مستوى&nbsp;الوعي&nbsp;(المعروفة&nbsp;أيضا&nbsp;باسم&nbsp;متلازمة&nbsp;الذهان&nbsp;الخبيثة).&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لديك&nbsp;مرض&nbsp;باركنسون&nbsp;أو&nbsp;الخرف.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت&nbsp;تعرف&nbsp;أن&nbsp;لديك&nbsp;مستويات&nbsp;منخفضة&nbsp;من&nbsp;خلايا&nbsp;الدم&nbsp;البيضاء&nbsp;في&nbsp;الماضي&nbsp;(والتي&nbsp;قد&nbsp;تكون&nbsp;أو&nbsp;لا&nbsp;تكون&nbsp;ناجمة&nbsp;عن&nbsp;أدوية&nbsp;أخرى).&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت&nbsp;مصاب&nbsp;بالسكري.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت مصابا بالصرع.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت&nbsp;كرجل&nbsp;قد تعرضت في&nbsp;أي&nbsp;وقت&nbsp;مضى&nbsp;لانتصاب&nbsp;لفترات&nbsp;طويلة&nbsp;أو&nbsp;مؤلمة.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كانت&nbsp;لديك&nbsp;مشاكل&nbsp;في&nbsp;التحكم&nbsp;في&nbsp;درجة&nbsp;حرارة&nbsp;جسمك&nbsp;أو&nbsp;ارتفاع&nbsp;في&nbsp;درجة&nbsp;الحرارة.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت&nbsp;تعاني&nbsp;من&nbsp;مشاكل&nbsp;في&nbsp;الكلى.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كانت&nbsp;لديك&nbsp;مشاكل&nbsp;في&nbsp;الكبد.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان&nbsp;لديك&nbsp;مستوى&nbsp;عال&nbsp;بشكل&nbsp;غير&nbsp;طبيعي&nbsp;من&nbsp;هرمون&nbsp;البرولاكتين&nbsp;في&nbsp;دمك&nbsp;أو&nbsp;إذا&nbsp;كان&nbsp;لديك&nbsp;ورم&nbsp;يعتمد&nbsp;على&nbsp;البرولاكتين.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك&nbsp;أو&nbsp;أي&nbsp;شخص&nbsp;آخر&nbsp;في&nbsp;عائلتك&nbsp;تاريخ&nbsp;من&nbsp;جلطات&nbsp;الدم،&nbsp;حيث&nbsp;أن&nbsp;مضادات&nbsp;الذهان&nbsp;ترتبط&nbsp;بتكوين&nbsp;جلطات&nbsp;دموية.&nbsp;</p><p dir="RTL">إذا&nbsp;لم&nbsp;تكن&nbsp;متأكدا&nbsp;مما&nbsp;إذا&nbsp;كان&nbsp;أي&nbsp;مما&nbsp;سبق&nbsp;ينطبق&nbsp;عليك،&nbsp;تحدث&nbsp;مع&nbsp;طبيبك&nbsp;أو&nbsp;الصيدلي&nbsp;قبل&nbsp;استخدام&nbsp;ريسيدرا.&nbsp;</p><p dir="RTL">نادرا جدا قد&nbsp;يظهر بشكل خطير&nbsp;انخفاض في أعداد&nbsp;نوع&nbsp;معين&nbsp;من&nbsp;خلايا&nbsp;الدم&nbsp;البيضاء&nbsp;اللازمة&nbsp;لمكافحة&nbsp;العدوى&nbsp;في&nbsp;دمك&nbsp;مع&nbsp;المرضى&nbsp;الذين&nbsp;يتناولون&nbsp;ريسيدرا،&nbsp;قد&nbsp;يتحقق&nbsp;طبيبك&nbsp;من&nbsp;عدد&nbsp;خلايا&nbsp;الدم&nbsp;البيضاء.&nbsp;</p><p dir="RTL">قد&nbsp;يتسبب&nbsp;ريسيدرا&nbsp;في&nbsp;زيادة&nbsp;وزنك.&nbsp;قد&nbsp;تؤثر&nbsp;زيادة&nbsp;الوزن&nbsp;بشكل&nbsp;كبير&nbsp;على&nbsp;صحتك.&nbsp;يجب&nbsp;على&nbsp;طبيبك&nbsp;قياس&nbsp;وزن&nbsp;الجسم&nbsp;بانتظام.&nbsp;</p><p dir="RTL">كما&nbsp;لوحظ&nbsp;ظهور&nbsp;مرض&nbsp;السكري&nbsp;أو&nbsp;تفاقم&nbsp;مرض&nbsp;السكري&nbsp;الموجود&nbsp;مسبقا&nbsp;مع&nbsp;المرضى&nbsp;الذين&nbsp;يتناولون&nbsp;ريسيدرا،&nbsp;يجب&nbsp;على&nbsp;طبيبك&nbsp;التحقق&nbsp;من&nbsp;وجود&nbsp;علامات&nbsp;ارتفاع&nbsp;نسبة&nbsp;السكر&nbsp;في&nbsp;الدم.&nbsp;يجب&nbsp;مراقبة&nbsp;الجلوكوز&nbsp;في&nbsp;الدم&nbsp;بانتظام&nbsp;في&nbsp;المرضى&nbsp;الذين&nbsp;يعانون&nbsp;من&nbsp;مرض&nbsp;السكري&nbsp;الموجود&nbsp;مسبقا.&nbsp;</p><p dir="RTL">يرفع&nbsp;ريسيدرا&nbsp;عادة&nbsp;من&nbsp;مستويات&nbsp;هرمون&nbsp;يسمى&nbsp;&quot;البرولاكتين&quot;.&nbsp;قد&nbsp;يسبب&nbsp;هذا أعراضا&nbsp;جانبية&nbsp;مثل&nbsp;اضطرابات&nbsp;الدورة&nbsp;الشهرية&nbsp;أو&nbsp;مشاكل&nbsp;الخصوبة&nbsp;لدى&nbsp;النساء،&nbsp;وتورم&nbsp;الثدي&nbsp;لدى&nbsp;الرجال&nbsp;(انظر&nbsp;الأعراض&nbsp;الجانبية&nbsp;المحتملة).&nbsp;في&nbsp;حالة&nbsp;حدوث&nbsp;مثل&nbsp;هذه&nbsp;الأعراض&nbsp;الجانبية،&nbsp;يوصى&nbsp;بتقييم&nbsp;مستوى&nbsp;البرولاكتين&nbsp;في&nbsp;الدم.&nbsp;</p><p dir="RTL">خلال&nbsp;اجراء&nbsp;عملية&nbsp;في&nbsp;العين&nbsp;لعلاج&nbsp;غيوم&nbsp;العدسة&nbsp;(إعتام عدسة العين)،&nbsp;قد لا يزيد حجم الحدقة&nbsp;(الدائرة&nbsp;السوداء&nbsp;في&nbsp;منتصف&nbsp;عينيك)&nbsp;بالشكل المطلوب.&nbsp;بالإضافة إلي أن&nbsp;القزحية&nbsp;(الجزء&nbsp;الملون&nbsp;من&nbsp;العين)&nbsp;قد&nbsp;تصبح&nbsp;مرنة&nbsp;أثناء&nbsp;الجراحة&nbsp;مما قد يؤدي&nbsp;إلى&nbsp;تلف&nbsp;العين.&nbsp;إذا&nbsp;كنت&nbsp;تخطط&nbsp;لإجراء&nbsp;عملية&nbsp;في&nbsp;عينيك،&nbsp;تأكد&nbsp;من&nbsp;أن&nbsp;تخبر&nbsp;طبيب&nbsp;العيون&nbsp;أنك&nbsp;تتناول&nbsp;هذا&nbsp;الدواء.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كبار&nbsp;السن&nbsp;الذين&nbsp;يعانون&nbsp;من&nbsp;الخرف</strong>&nbsp;</p><p dir="RTL">في&nbsp;المرضى&nbsp;المسنين&nbsp;الذين&nbsp;يعانون&nbsp;من&nbsp;الخرف،&nbsp;هناك&nbsp;خطر&nbsp;متزايد&nbsp;من&nbsp;حدوث&nbsp;السكتة&nbsp;الدماغية.&nbsp;يجب&nbsp;أن&nbsp;لا&nbsp;تقم بتناول&nbsp;ريسبيريدون&nbsp;إذا&nbsp;كان&nbsp;لديك&nbsp;الخرف&nbsp;الناجم&nbsp;عن&nbsp;السكتة&nbsp;الدماغية.&nbsp;</p><p dir="RTL">أثناء&nbsp;العلاج&nbsp;باستخدام&nbsp;ريسبيريدون&nbsp;يجب&nbsp;أن تتابع مع طبيبك بشكل متكرر.&nbsp;</p><p dir="RTL">يجب&nbsp;طلب&nbsp;العلاج&nbsp;الطبي&nbsp;على&nbsp;الفور&nbsp;إذا&nbsp;لاحظت&nbsp;أنت&nbsp;أو&nbsp;مقدم&nbsp;الرعاية&nbsp;أن&nbsp;هناك&nbsp;تغييرا&nbsp;مفاجئا&nbsp;في&nbsp;حالتك&nbsp;العقلية&nbsp;أو&nbsp;ضعف&nbsp;مفاجئ&nbsp;أو&nbsp;تنميل&nbsp;في&nbsp;وجهك&nbsp;أو&nbsp;ذراعيك&nbsp;أو&nbsp;أرجلك،&nbsp;ولا&nbsp;سيما&nbsp;على&nbsp;جانب&nbsp;واحد،&nbsp;أو&nbsp;أصبح كلامك مبهما،&nbsp;حتى&nbsp;ولو&nbsp;لفترة&nbsp;قصيرة&nbsp;من&nbsp;الوقت.&nbsp;قد&nbsp;تكون&nbsp;هذه&nbsp;علامات&nbsp;حدوث&nbsp;السكتة&nbsp;الدماغية.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال&nbsp;والمراهقين</strong>&nbsp;</p><p dir="RTL">قبل&nbsp;البدء&nbsp;في&nbsp;علاج&nbsp;اضطراب&nbsp;السلوك،&nbsp;يجب التأكد من&nbsp;استبعاد&nbsp;الأسباب&nbsp;الأخرى&nbsp;للسلوك&nbsp;العدواني.&nbsp;</p><p dir="RTL">إذا&nbsp;ظهر&nbsp;التعب والملل&nbsp;أثناء&nbsp;العلاج&nbsp;باستخدام&nbsp;ريسبيريدون،&nbsp;فإن&nbsp;تغيير&nbsp;ميعاد تناول الدواء&nbsp;قد&nbsp;يحسن&nbsp;من صعوبات&nbsp;الانتباه.&nbsp;</p><p dir="RTL">قبل&nbsp;البدء&nbsp;في&nbsp;العلاج&nbsp;قد يتم قياس الوزن&nbsp;الخاص&nbsp;بك&nbsp;أو&nbsp;بطفلك،&nbsp;ومن الممكن مراقبة الوزن&nbsp;بانتظام&nbsp;أثناء&nbsp;العلاج.&nbsp;</p><p dir="RTL">وقد&nbsp;ذكرت&nbsp;دراسة&nbsp;صغيرة&nbsp;وغير&nbsp;حاسمة&nbsp;زيادة&nbsp;في&nbsp;الطول لدي&nbsp;الأطفال&nbsp;الذين&nbsp;تناولوا&nbsp;ريسبيريدون،&nbsp;ولكن&nbsp;من غير المعروف&nbsp;ما&nbsp;إذا&nbsp;كان&nbsp;هذا&nbsp;من&nbsp;تأثير&nbsp;الدواء&nbsp;أو&nbsp;نتيجة&nbsp;سبب&nbsp;آخر.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أدوية&nbsp;أخرى&nbsp;و&nbsp;ريسيدرا</strong>&nbsp;</p><p dir="RTL">أخبر&nbsp;طبيبك&nbsp;أو&nbsp;الصيدلي&nbsp;إذا&nbsp;كنت&nbsp;تتناول،&nbsp;أو تناولت&nbsp;مؤخرا&nbsp;أو&nbsp;قد&nbsp;تتناول&nbsp;أي&nbsp;أدوية&nbsp;أخرى.&nbsp;</p><p dir="RTL"><strong>من&nbsp;المهم&nbsp;جدا&nbsp;التحدث&nbsp;إلى&nbsp;طبيبك&nbsp;أو&nbsp;الصيدلي&nbsp;إذا&nbsp;كنت&nbsp;تتناول&nbsp;أيا&nbsp;مما&nbsp;يلي:</strong>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية&nbsp;التي&nbsp;تعمل&nbsp;على&nbsp;المخ&nbsp;مثل&nbsp;التي تساعدك علي الهدوء&nbsp;(البنزوديازيبينات)&nbsp;أو&nbsp;بعض&nbsp;أدوية&nbsp;علاج الألم&nbsp;(الأفيونات)،&nbsp;وأدوية&nbsp;الحساسية&nbsp;(بعض&nbsp;مضادات&nbsp;الهستامين)،&nbsp;حيث&nbsp;أن&nbsp;ريسبيريدون&nbsp;قد&nbsp;يزيد&nbsp;من&nbsp;التأثير&nbsp;المهدئ&nbsp;لكل&nbsp;هذه&nbsp;الأدوية.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدویة&nbsp;التي&nbsp;قد&nbsp;تغیر&nbsp;من&nbsp;النشاط&nbsp;الکھربي&nbsp;لقلبك،&nbsp;مثل&nbsp;أدویة&nbsp;الملاریا،&nbsp;وأدوية علاج&nbsp;مشاکل&nbsp;ضربات&nbsp;القلب،&nbsp;وأدوية&nbsp;الحساسية&nbsp;(مضادات&nbsp;الھستامین)،&nbsp;وبعض&nbsp;مضادات&nbsp;الاكتئاب&nbsp;أو&nbsp;الأدویة&nbsp;الأخرى&nbsp;للمشاکل&nbsp;العقلیة.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية&nbsp;التي&nbsp;تسبب&nbsp;بطء في&nbsp;ضربات&nbsp;القلب.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية&nbsp;التي&nbsp;تسبب&nbsp;انخفاض&nbsp;البوتاسيوم&nbsp;في&nbsp;الدم&nbsp;(مثل&nbsp;أنواع معينة من&nbsp;مدرات&nbsp;البول).&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية&nbsp;علاج&nbsp;ارتفاع&nbsp;ضغط&nbsp;الدم.&nbsp;من الممكن أن يتسبب&nbsp;ريسيدرا&nbsp;في&nbsp;خفض&nbsp;ضغط&nbsp;الدم.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية&nbsp;لعلاج&nbsp;مرض&nbsp;باركنسون&nbsp;(مثل&nbsp;ليڨودوبا).&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أقراص&nbsp;المياه&nbsp;(مدرات&nbsp;البول)&nbsp;المستخدمة&nbsp;في&nbsp;علاج&nbsp;مشاكل&nbsp;القلب&nbsp;أو&nbsp;تورم&nbsp;أجزاء&nbsp;من&nbsp;الجسم&nbsp;بسبب&nbsp;تراكم&nbsp;الكثير&nbsp;من&nbsp;السوائل&nbsp;(مثل&nbsp;فيوروسيميد&nbsp;أو&nbsp;كلوروثيازيد).&nbsp;تناول&nbsp;ريسيدرا&nbsp;بمفرده أو&nbsp;مع&nbsp;فيوروسيميد،&nbsp;قد&nbsp;يتسبب في تزايد خطورة الإصابة&nbsp;بالسكتة&nbsp;الدماغية&nbsp;أو&nbsp;الموت&nbsp;في&nbsp;كبار&nbsp;السن&nbsp;الذين&nbsp;يعانون&nbsp;من&nbsp;الخرف.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تزيد من نشاط الجهاز العصبي المركزي (المنشطات النفسية ، مثل الميثيلفينيديت).</p><p dir="RTL"><strong>الأدوية&nbsp;التالية&nbsp;قد&nbsp;تقلل&nbsp;من&nbsp;تأثير&nbsp;ريسبيريدون</strong>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفامبيسين&nbsp;(دواء&nbsp;لعلاج&nbsp;بعض&nbsp;العدوى).&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كاربامازيبين،&nbsp;فينيتوين&nbsp;(أدوية&nbsp;الصرع).&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فينوباربيتال.&nbsp;</p><p dir="RTL">إذا&nbsp;كنت&nbsp;قد&nbsp;بدأت&nbsp;أو&nbsp;توقفت&nbsp;عن&nbsp;تناول&nbsp;مثل&nbsp;هذه&nbsp;الأدوية&nbsp;قد&nbsp;تحتاج&nbsp;إلى&nbsp;جرعة&nbsp;مختلفة&nbsp;من&nbsp;ريسبيريدون.&nbsp;</p><p dir="RTL"><strong>الأدوية&nbsp;التالية&nbsp;قد&nbsp;تزيد&nbsp;من&nbsp;تأثير&nbsp;ريسبيريدون</strong>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كينيدين&nbsp;(يستخدم&nbsp;لأنواع&nbsp;معينة&nbsp;من&nbsp;أمراض&nbsp;القلب).&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات&nbsp;الاكتئاب&nbsp;مثل&nbsp;الباروكستين،&nbsp;فلوكستين،&nbsp;مضادات&nbsp;الاكتئاب&nbsp;ثلاثية&nbsp;الحلقات.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية&nbsp;المعروفة&nbsp;باسم&nbsp;حاصرات&nbsp;بيتا&nbsp;(المستخدمة&nbsp;لعلاج&nbsp;ارتفاع&nbsp;ضغط&nbsp;الدم).&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فينوثيازين&nbsp;(مثل&nbsp;الأدوية&nbsp;المستخدمة&nbsp;لعلاج&nbsp;الذهان&nbsp;أو&nbsp;للتهدئة).&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيميتيدين،&nbsp;رانيتيدين&nbsp;(حاصرات&nbsp;حموضة&nbsp;المعدة).&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إيتراكونازول&nbsp;وكيتوكونازول&nbsp;(أدوية&nbsp;لعلاج&nbsp;الالتهابات&nbsp;الفطرية).&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية&nbsp;معينة&nbsp;تستخدم&nbsp;في&nbsp;علاج&nbsp;فيروس&nbsp;نقص&nbsp;المناعة&nbsp;البشرية&nbsp;/&nbsp;الإيدز،&nbsp;مثل&nbsp;ريتونافير.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ڨيراباميل،&nbsp;وهو&nbsp;دواء&nbsp;يستخدم&nbsp;لعلاج&nbsp;ارتفاع&nbsp;ضغط&nbsp;الدم&nbsp;و&nbsp;/&nbsp;أو&nbsp;إيقاع&nbsp;القلب&nbsp;غير&nbsp;الطبيعي.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيرترالين&nbsp;وفلوڨوكسامين،&nbsp;والأدوية&nbsp;المستخدمة&nbsp;لعلاج&nbsp;الاكتئاب&nbsp;وغيرها&nbsp;من&nbsp;الاضطرابات&nbsp;النفسية.&nbsp;</p><p dir="RTL">إذا&nbsp;كنت&nbsp;قد بدأت&nbsp;أو&nbsp;توقفت&nbsp;عن&nbsp;تناول&nbsp;مثل&nbsp;هذه&nbsp;الأدوية&nbsp;قد&nbsp;تحتاج&nbsp;إلى&nbsp;جرعة&nbsp;مختلفة&nbsp;من&nbsp;ريسبيريدون.&nbsp;</p><p dir="RTL">إذا&nbsp;لم&nbsp;تكن&nbsp;متأكدا&nbsp;مما&nbsp;إذا&nbsp;كان&nbsp;أي&nbsp;مما&nbsp;سبق&nbsp;ينطبق&nbsp;عليك،&nbsp;تحدث&nbsp;مع&nbsp;طبيبك&nbsp;أو&nbsp;الصيدلي&nbsp;قبل&nbsp;استخدام&nbsp;ريسيدرا.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ريسيدرا&nbsp;مع&nbsp;الطعام&nbsp;والشراب&nbsp;والكحول</strong>&nbsp;</p><p dir="RTL">يمكنك&nbsp;أن&nbsp;تتناول&nbsp;هذا&nbsp;الدواء&nbsp;مع&nbsp;أو&nbsp;بدون&nbsp;الطعام.&nbsp;يجب&nbsp;تجنب&nbsp;شرب&nbsp;الكحول&nbsp;عند&nbsp;تناول&nbsp;ريسيدرا.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل&nbsp;والرضاعة&nbsp;الطبيعية&nbsp;والخصوبة</strong>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا&nbsp;كنتي&nbsp;حاملا&nbsp;أو&nbsp;تقومين بالرضاعة الطبيعية،&nbsp;أو تعتقدين أنك حاملا&nbsp;أو&nbsp;تخططين&nbsp;للإنجاب،&nbsp;اطلبي&nbsp;من&nbsp;طبيبك&nbsp;أو&nbsp;الصيدلي&nbsp;المشورة&nbsp;قبل&nbsp;تناول&nbsp;هذا&nbsp;الدواء.&nbsp;سوف&nbsp;يقرر&nbsp;طبيبك&nbsp;ما&nbsp;إذا&nbsp;كان&nbsp;بإمكانك&nbsp;تناوله.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد&nbsp;تظهر&nbsp;الأعراض&nbsp;التالية&nbsp;لدي&nbsp;الأطفال&nbsp;حديثي&nbsp;الولادة،&nbsp;من&nbsp;الأمهات&nbsp;اللاتي&nbsp;استخدمن&nbsp;ريسيدرا&nbsp;في&nbsp;الثلث&nbsp;الأخير&nbsp;من&nbsp;الحمل&nbsp;(الأشهر&nbsp;الثلاثة الأخيرة&nbsp;من&nbsp;الحمل):&nbsp;الارتعاش،&nbsp;وصلابة&nbsp;العضلات،&nbsp;و&nbsp;/&nbsp;أو&nbsp;الضعف،&nbsp;والنعاس،&nbsp;والتهيج،&nbsp;ومشاكل&nbsp;التنفس،&nbsp;وصعوبة&nbsp;التغذية.&nbsp;إذا&nbsp;بدأ أي من هذه الأعراض في الظهور علي&nbsp;طفلك&nbsp;قد&nbsp;تحتاجين&nbsp;إلى&nbsp;التواصل مع&nbsp;طبيبك.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من الممكن أن يرفع&nbsp;ريسيدرا&nbsp;من مستويات هرمون&nbsp;يسمى&nbsp;&quot;البرولاكتين&quot;&nbsp;مما&nbsp;قد&nbsp;يؤثر&nbsp;على&nbsp;الخصوبة&nbsp;(انظر&nbsp;الأعراض&nbsp;الجانبية&nbsp;المحتملة).&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام&nbsp;الآلات</strong>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تظهر&nbsp;دوخة وتعب، ومشاكل في الرؤية&nbsp;أثناء&nbsp;العلاج&nbsp;باستخدام&nbsp;ريسيدرا. لا&nbsp;تقم بالقيادة&nbsp;أو استخدام أي أدوات أو آلات دون التحدث إلى الطبيب أولاً.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول&nbsp;هذا الدواء بالضبط كما أخبرك&nbsp;طبيبك دائماً. استشر طبيبك أو الصيدلي إذا لم تكن متأكداً.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة&nbsp;الموصي&nbsp;بها كما يلي:</strong>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لعلاج مرض الفصام</strong>&nbsp;</p><p dir="RTL"><strong> </strong>&nbsp;</p><p dir="RTL"><strong>البالغين</strong>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جرعة البدء المعتادة&nbsp;هي&nbsp;2 ملجم يوميا، وقد&nbsp;ترتفع إلى 4 ملجم&nbsp;يوميا في اليوم الثاني.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ثم يمكن&nbsp;لطبيبك&nbsp;تعديل الجرعة الخاصة بك اعتماداً على كيفية استجابتك&nbsp;للعلاج.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; معظم الأشخاص&nbsp;يشعرون بتحسن مع جرعات يومية من 4 إلى 6 ملجم.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ويمكن تقسيم هذه الجرعة اليومية الكلية&nbsp;على جرعة&nbsp;واحدة&nbsp;أو اثنين في اليوم. سوف يخبرك&nbsp;طبيبك&nbsp;ما&nbsp;هو الأفضل بالنسبة لك.&nbsp;</p><p dir="RTL"><strong>كبار السن</strong>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جرعة&nbsp;البدء&nbsp;الخاصة بك&nbsp;عادة تكون 0.5 ملجم&nbsp;مرتين في اليوم.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن لطبيبك زيادة&nbsp;الجرعة الخاصة بك تدريجيا&nbsp;لتصل إلى&nbsp;1 إلى 2 ملجم مرتين في اليوم.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سوف يخبرك طبيبك ما هو الأفضل بالنسبة لك.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لعلاج&nbsp;الهوس</strong>&nbsp;</p><p dir="RTL"><strong> </strong>&nbsp;</p><p dir="RTL"><strong>البالغين</strong>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عادة ما تكون جرعة&nbsp;البداية هي&nbsp;2 ملجم&nbsp;مرة واحدة&nbsp;يوميا.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ثم يمكن&nbsp;لطبيبك&nbsp;تعديل الجرعة الخاصة بك اعتماداً على كيفية استجابتك&nbsp;للعلاج.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; معظم الأشخاص&nbsp;يشعرون بتحسن مع جرعات من&nbsp;1&nbsp;إلى 6 ملجم&nbsp;مرة واحدة يوميا.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كبار السن</strong>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جرعة&nbsp;البدء&nbsp;الخاصة بك&nbsp;عادة تكون 0.5 ملجم&nbsp;مرتين في اليوم.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن لطبيبك زيادة&nbsp;الجرعة الخاصة بك تدريجيا&nbsp;لتصل إلى&nbsp;1 إلى 2 ملجم مرتين في اليوم&nbsp;اعتماداً على كيفية استجابتك&nbsp;للعلاج.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لعلاج العدوان&nbsp;طويل الأمد&nbsp;في الأشخاص المصابين بخرف مرض الزهايمر</strong>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>البالغين (بما في ذلك كبار السن)</strong>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جرعة&nbsp;البدء&nbsp;الخاصة بك&nbsp;عادة تكون 0.25 ملجم&nbsp;مرتين في اليوم.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن لطبيبك زيادة&nbsp;الجرعة الخاصة بك تدريجيا&nbsp;اعتماداً على كيفية استجابتك&nbsp;للعلاج.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; معظم الأشخاص&nbsp;يشعرون بتحسن&nbsp;بتناول جرعة 0.5&nbsp;ملجم&nbsp;مرتين يوميا.&nbsp;قد يحتاج بعض المرضى&nbsp;جرعة&nbsp;1 ملجم مرتين يوميا.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي أن&nbsp;لا تتعدي&nbsp;مدة العلاج في المرضى الذين يعانون من خرف مرض الزهايمر 6 أسابيع.&nbsp;</p><p dir="RTL">التھیج المصاحب لاضطراب التوحد - الأطفال (الأطفال والمراھقون) :<br />یجب أن تكون جرعة ریسیدرا فردیة وفقًا للاستجابة والتحم ل للمریض. یمكن إعطاء الجرعة الیومیة الإجمالیة من ریسیدر ا مرة واحدة<br />یومیًا، أو یمكن تناول نصف الجرعة الیومیة الإجمالیة مرتین یومیًا .<br />بالنسبة للمرضى الذین یقل وزن الجسم عن 20 كجم، ابدأ الجرعات عند 0.25 ملجم في الیوم. للمرض ى الذین وزن جسمھم أكبر من أو<br />یساوي 20 كجم، ابدأ الجرعات عند 0.5 ملجم في الیوم. بعد أربعة أیام على الأقل، یمكن زیادة الجرعة إلى الجرعة الموصى بھا 0.5<br />ملجم في الیو م للمرضى الذین یقل وزنھم عن 20 كجم و 1.0 ملجم یومیًا للمرضى الذین یزید وزنھم عن 20 كجم أو یساویھ.<br />حافظ على ھذه الجرعة لمدة 14 یومًا على الأقل. في المرضى الذین لا یحققون ما یكفي م ن الاستجاب ة السریریة، یمكن زیادة الجرعة<br />على فترات أسبوعین أو أكثر، بزیادات قدرھا 0.25 مل جم في الیوم للمرضى الذین یقل وزنھم عن 20 كجم، أو زیادات 0.5 ملجم یومیًا<br />للمرضى الذین تزید أعمارھم عن أو یساوي 20 كجم.<br />نطاق الجرعة الفعالة ھو 0.5 ملجم إلى 3 ملجم في الیوم. لا توجد بیانات متاحة عن الجرعات للأطفال الذین یقل وزنھم عن 15 كجم.<br />بمجرد تحقیق الاستجابة السریریة الكافیة والمحافظة علیھا، فكر في خفض الجرعة تدریجیً ا لتحقیق التوازن الأمثل بین الفعالیة والأمان.<br />یجب على الطبیب الذي یختار استخدام ریسیدرا لفترات طویلة إعادة تقییم المخاطر طویلة الأجل بشكل دوري وفوائد الدواء للمریض<br />الفردي .<br />قد یستفید المرضى الذین یعانون من نعاس مستمر من جرعة یومیة یتم إعطاؤھا في وقت النوم أو إعطاء نصف الجرعة الیومیة مرتین<br />في الیوم أو تقلیل الجرعة .</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاستخدام&nbsp;في الأطفال والمراهقين</strong>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يجب علاج&nbsp;الأطفال والمراهقين دون سن 18 عاماً&nbsp;باستخدام&nbsp;ريسيدرا&nbsp;لمرض الفصام أو الهوس.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لعلاج اضطراب السلوك</strong>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">تعتمد&nbsp;الجرعة&nbsp;على وزن طفلك:&nbsp;</p><p dir="RTL">للأطفال الذين&nbsp;يزنون&nbsp;أقل من 50 كجم&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تكون جرعة البداية&nbsp;عادة&nbsp;هي&nbsp;0.25 ملجم&nbsp;مرة واحدة في اليوم.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ويمكن زيادة الجرعة&nbsp;كل&nbsp;يوم&nbsp;بعد يوم&nbsp;على مراحل&nbsp;من 0.25 ملجم&nbsp;يوميا.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة&nbsp;المعتادة&nbsp;للحفاظ على الحالة&nbsp;هي&nbsp;من&nbsp;0.25&nbsp;ملجم&nbsp;إلى 0.75 ملجم&nbsp;مرة واحدة&nbsp;يوميا.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">للأطفال الذين&nbsp;يزنون&nbsp;50&nbsp;كجم&nbsp;أو أكثر&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تكون جرعة البداية&nbsp;عادة&nbsp;هي&nbsp;0.5 ملجم&nbsp;مرة واحدة في اليوم.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ويمكن زيادة الجرعة&nbsp;كل&nbsp;يوم&nbsp;بعد يوم&nbsp;على مراحل&nbsp;من 0.5 ملجم&nbsp;يوميا.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة&nbsp;المعتادة&nbsp;للحفاظ&nbsp;على&nbsp;الحالة&nbsp;هي&nbsp;من 0.5&nbsp;ملجم&nbsp;إلى&nbsp;1.5&nbsp;ملجم&nbsp;مرة واحدة&nbsp;يوميا.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي أن&nbsp;لا تتعدي&nbsp;مدة العلاج في المرضى الذين يعانون من&nbsp;اضطرابات السلوك&nbsp;6 أسابيع.&nbsp;</p><p dir="RTL">لا يجب علاج&nbsp;الأطفال دون سن 5 سنوات من العمر&nbsp;باستخدام&nbsp;ريسيدرا&nbsp;لمرض اضطراب السلوك.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأشخاص المصابين بمشاكل في الكلي أو الكبد</strong>&nbsp;</p><p dir="RTL">بغض النظر عن المرض&nbsp;الذي يتم علاجه، ينبغي&nbsp;أن تقل جرعات البدء والجرعات التالية من&nbsp;ريسبيريدون&nbsp;إلي النصف. وينبغي&nbsp;أن تكون&nbsp;زيادة الجرعة&nbsp;بشكل&nbsp;أبطأ في هؤلاء المرضى.&nbsp;</p><p dir="RTL">ينبغي أن&nbsp;يستخدم&nbsp;ريسبيريدون&nbsp;بحذر في هذه الفئة من المرضى.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيفية التناول</strong>&nbsp;</p><p dir="RTL">للاستخدام عن طريق الفم.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>محلول&nbsp;ريسيدرا&nbsp;عن طريق الفم</strong>&nbsp;</p><p dir="RTL">يتوفر مع المحلول محقنة.&nbsp;وينبغي استخدامها&nbsp;لمساعدتك على قياس&nbsp;الكمية&nbsp;المطلوبة من الدواء بدقة.&nbsp;</p><p dir="RTL">اتبع الخطوات التالية:&nbsp;</p><p dir="RTL">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قم بإزالة&nbsp;الغطاء&nbsp;المقاوم للطفل. اضغط على الغطاء البلاستيكي لأسفل&nbsp;أثناء لفه في&nbsp;اتجاه&nbsp;عكس&nbsp;عقارب الساعة (الشكل 1)&nbsp;</p><p dir="RTL">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قم بإدخال المحقنة&nbsp;في الزجاجة&nbsp;</p><p dir="RTL">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اثناء الإمساك بحلقة المحقنة السفلية، قم بسحب حلقة المحقنة العلوية&nbsp;حتى&nbsp;تصل إلى العلامة التي تناظر عدد&nbsp;الملليلترات&nbsp;أو ملجم التي تحتاج تناولها&nbsp;(الشكل 2)&nbsp;</p><p dir="RTL">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قم بالإمساك بحلقة المحقنة السفلية، وأزل المحقنة بأكملها&nbsp;من الزجاجة (الشكل 3)&nbsp;</p><p dir="RTL">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أفرغ المحقنة في أي مشروب غير كحولي، باستثناء الشاي. وذلك عن طريق&nbsp;الضغط&nbsp;على&nbsp;حلقة المحقنة العلوية لأسفل&nbsp;</p><p dir="RTL">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قم&nbsp;بإغلاق الزجاجة&nbsp;</p><p dir="RTL">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قم بشطف المحقنة&nbsp;باستخدام&nbsp;بعض الماء.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا&nbsp;تناولت&nbsp;ريسيدرا&nbsp;أكثر مما يجب</strong>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قم بمراجعة&nbsp;طبيب على الفور.&nbsp;وقم باصطحاب&nbsp;علبة الدواء معك.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة تناول جرعة زائدة قد&nbsp;تشعر&nbsp;بالنعاس أو التعب، أو&nbsp;بحركات&nbsp;للجسم&nbsp;غير طبيعية لديك،&nbsp;ومشاكل&nbsp;في الوقوف&nbsp;والمشي، وشعور&nbsp;بالدوار بسبب انخفاض ضغط الدم، أو دقات قلب غير طبيعية&nbsp;أو&nbsp;نوبات.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا&nbsp;نسيت&nbsp;تناول&nbsp;ريسيدرا</strong>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا نسيت تناول جرعة، فتناولها بمجرد أن تتذكر. ومع ذلك، إذا كان الوقت قريبا من ميعاد الجرعة التالية، تخطي الجرعة الفائتة&nbsp;واستمر في تناول الدواء&nbsp;كالمعتاد. إذا&nbsp;نسيت تناول جرعتين أو أكثر، تواصل مع&nbsp;طبيبك.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا&nbsp;تتناول&nbsp;جرعة مزدوجة (جرعتين في نفس الوقت)&nbsp;لتعوض&nbsp;الجرعة المنسيّة.</strong>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا&nbsp;توقفت عن تناول&nbsp;ريسيدرا</strong>&nbsp;</p><p dir="RTL">يجب عليك عدم التوقف عن&nbsp;تناول&nbsp;هذا الدواء إلا إذا صرح&nbsp;طبيبك بذلك. قد&nbsp;تعاودك&nbsp;أعراضك مرة أخري. إذا قرر طبيبك&nbsp;وقف هذا الدواء، قد&nbsp;تنخفض&nbsp;جرعتك&nbsp;تدريجيا على مدى بضعة أيام.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي ريسيدرا على حمض البنزويك.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي هذا الدواء على 2 ملجم من حمض البنزويك في كل 1 مل من المحلول. حمض البنزويك قد يزيد من اليرقان (اصفرار الجلد والعينين) عند الأطفال حديثي الولادة (حتى عمر 4 أسابيع).</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت&nbsp;لديك أي أسئلة أخرى عن استخدام هذا الدواء، اسأل طبيبك أو الصيدلي.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن لهذا الدواء أن يسبب أعراض جانبية، على الرغم من أنه ليس كل شخص يتعرض لها.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أخبر طبيبك فورا إذا كنت:</strong>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعرضت&nbsp;لتجلط الدم في الأوردة، لا سيما في الساقين (تشمل الأعراض تورم وألم واحمرار في الساق)، والتي يمكن&nbsp;أن تنتقل&nbsp;عن طريق الأوعية الدموية إلى الرئتين مما تسبب ألم في الصدر وصعوبة في التنفس. إذا لاحظت أي من هذه الأعراض التمس&nbsp;المشورة الطبية فورا.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مصابا بالخرف وتعرضت&nbsp;لتغيير مفاجئ في الحالة العقلية أو ضعف مفاجئ أو&nbsp;تنميل&nbsp;في الوجه، والذراعين أو الساقين، ولا سيما على جانب واحد، أو&nbsp;أصبح كلامك مبهما، حتى لفترة قصيرة من الزمن. &nbsp;قد تكون هذه علامات السكتة الدماغية.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعرضت&nbsp;للحمى، وتصلب العضلات، والتعرق أو خفض مستوى الوعي (اضطراب يسمى &quot;متلازمة&nbsp;الذهان&nbsp;الخبيثة&quot;). قد تكون هناك حاجة إلى العلاج الطبي الفوري.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعرضت كرجل لانتصاب&nbsp;لفترة&nbsp;طويلة&nbsp;أو&nbsp;مؤلمة.&nbsp; وهذا ما يسمى&nbsp;بالقُسَاح. قد تكون هناك حاجة إلى العلاج الطبي الفوري.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعرضت&nbsp;لحركات&nbsp;متناغمة لاإرادية&nbsp;للسان والفم والوجه.&nbsp; قد تكون هناك حاجة&nbsp;للتوقف عن تناول&nbsp;ريسبيريدون.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعرضت&nbsp;لرد فعل&nbsp;تحسسي&nbsp;شديد&nbsp;يتميز بالحمى وتورم الفم والوجه، والشفة أو اللسان، ضيق في التنفس، وحكة، طفح الجلد أو انخفاض في ضغط الدم.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">وقد&nbsp;تحدث الأعراض&nbsp;الجانبية التالية:&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة&nbsp;جداً (قد&nbsp;تؤثر على أكثر من 1 في 10 أشخاص):</strong>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;  صعوبة في البقاء نائماً أو&nbsp;التساقط.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرعاش: قد تتضمن هذه الحالة:&nbsp;بطأ أو خلل في الحركة&nbsp;والإحساس بتصلب أو&nbsp;تشنج&nbsp;العضلات (تصبح حركتك&nbsp;متشنجة)، وأحيانا&nbsp;الإحساس بأن الحركة قد&nbsp;&quot;تجمدت&quot;&nbsp;ثم عادت من جديد. علامات أخرى للرعاش&nbsp;وتشمل&nbsp;تعثر المشي، ورعشة حتى في وقت الراحة، وزيادة اللعاب و/أو&nbsp;سيلان اللعاب، وفقدان التعبير على الوجه.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالنعاس، أو&nbsp;ضعف الانتباه.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة&nbsp;(قد تؤثر&nbsp;على ما يصل إلى 1 في 10 أشخاص):</strong>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الالتهاب الرئوي، وعدوى الصدر (التهاب الشعب الهوائية)، أعراض نزلات البرد، والتهاب الجيوب&nbsp;الأنفية، التهاب المسالك البولية، والتهاب الأذن،&nbsp;الشعور بأن لديك إنفلونزا.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ظهور ارتفاع&nbsp;في&nbsp;مستويات هرمون يدعى &quot;البرولاكتين&quot; في اختبار الدم (الذي قد أو قد لا يسبب أعراض).&nbsp; أعراض ارتفاع&nbsp;البرولاكتين&nbsp;تظهر بصورة غير شائعة ومن الممكن أن تتضمن انتفاخ&nbsp;في الثدي&nbsp;لدي&nbsp;الرجال وصعوبة في الحصول على أو المحافظة على الانتصاب، تناقص الرغبة الجنسية أو&nbsp;أعراض&nbsp;العجز الجنسي الأخرى.&nbsp; قد تشمل&nbsp;في النساء&nbsp;عدم&nbsp;الشعور بالراحة في&nbsp;الثدي، تسرب الحليب من الثديين، وغياب فترات الطمث، أو مشاكل أخرى&nbsp;في الدورة الشهرية أو&nbsp;الخصوبة&nbsp;لديك.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الوزن، زيادة الشهية، انخفاض الشهية.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب النوم، التهيج، والاكتئاب، والقلق، والأرق.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خلل&nbsp;التوتر: تشمل&nbsp;أعراض هذه الحالة&nbsp;تقلص&nbsp;لاإرادي في&nbsp;العضلات&nbsp;بصورة&nbsp;بطيئة أو مستمرة.&nbsp; وفي حين أنه يمكن أن تنطوي على أي جزء من الجسم (وقد ينتج عنها وضع الجسد في صورة&nbsp;غير طبيعية)، خلل&nbsp;التوتر&nbsp;غالباً ما ينطوي على عضلات الوجه، بما في ذلك حركات غير طبيعية للعيون والفم واللسان أو الفك.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خلل&nbsp;الحركة:&nbsp;تشمل أعراض هذه الحالة حركات عضلية لاإرادية، ويمكن أن&nbsp;تشمل الحركات المتكررة أو المتشنجة&nbsp;أو&nbsp;الملتوية، أو الوخز.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الارتعاش&nbsp;(الارتجاف).&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضبابية الرؤية، وعدوي&nbsp;العين أو &quot;العين الوردية&quot;.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرعة معدل ضربات القلب، ارتفاع ضغط الدم وضيق في التنفس.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب في الحلق والسعال، ونزيف في&nbsp;الأنف، انسداد&nbsp;الأنف.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألام في البطن، وعدم&nbsp;الشعور بالراحة في البطن، القيء، الغثيان، والإمساك، والإسهال، عسر الهضم، جفاف الفم، ألم في الأسنان.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار الجلد،&nbsp;الطفح&nbsp;الجلدي.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنجات العضلات،&nbsp;ألام&nbsp;العظام أو العضلات، ألم الظهر، ألم&nbsp;المفاصل.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السلس البولي&nbsp;(عدم التحكم&nbsp;في البول).&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم في الجسم، والذراعين أو الساقين، حمى،&nbsp;وألم في&nbsp;الصدر، الضعف، الإرهاق (التعب)، والألم.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السقوط.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة&nbsp;(قد تؤثر&nbsp;على ما يصل إلى 1 في 100 شخص):</strong>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى ممرات التنفس، التهاب المثانة،&nbsp;عدوى&nbsp;العين، التهاب اللوزتين، العدوى الفطرية للأظافر، التهاب الجلد، وعدوى تقتصر على منطقة واحدة من الجلد أو جزء من الجسم، والعدوى الفيروسية، التهاب الجلد الناجم عن العث.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص&nbsp;في نوع&nbsp;من&nbsp;خلايا الدم البيضاء التي تساعد على حمايتك ضد العدوى، وانخفاض عدد خلايا الدم البيضاء&nbsp;ونقص&nbsp;في&nbsp;الصفائح الدموية (خلايا الدم التي تساعدك على وقف النزيف)، فقر الدم، وانخفاض في&nbsp;خلايا&nbsp;الدم الحمراء، زيادة في&nbsp;الحمضات&nbsp;(نوع من&nbsp;خلايا&nbsp;الدم البيضاء) في الدم.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات تحسسية.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض السكري&nbsp;أو تفاقم مرض السكري،&nbsp;ارتفاع مستوي&nbsp;السكر في الدم، والإفراط في شرب المياه.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوزن، وفقدان الشهية مما يؤدي إلى سوء التغذية وانخفاض الوزن.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة نسبة&nbsp;الكوليسترول&nbsp;في الدم.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مزاج&nbsp;مبتهج&nbsp;(هوس)، الارتباك، انخفاض الدوافع&nbsp;الجنسية، العصبية،&nbsp;الكوابيس.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خلل&nbsp;الحركة&nbsp;المتأخر (ارتعاش او ارتجاج&nbsp;الحركات التي لا يمكنك التحكم&nbsp;بها&nbsp;في وجهك أو اللسان أو أجزاء أخرى من الجسم).&nbsp; أخبر طبيبك فورا إذا واجهت حركات&nbsp;متناغمة لاإرادية&nbsp;للسان والفم والوجه.&nbsp; قد تكون هناك حاجة للتوقف عن تناول&nbsp;ريسيدرا.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفقدان المفاجئ لوصول الدم إلى&nbsp;المخ&nbsp;(السكتة الدماغية أو السكتة الدماغية &quot;المصغرة&quot;).&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم القدرة&nbsp;على الاستجابة للمحفزات، فقدان الوعي،&nbsp;انخفاض&nbsp;مستوى الوعي.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنج (نوبات)، إغماء.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رغبة&nbsp;غير مريحة&nbsp;في تحريك أجزاء الجسم واضطراب التوازن واختلال التوافق العضلي، والدوخة عند الوقوف، اضطراب في الانتباه، مشاكل في الكلام، فقدان حاسة التذوق&nbsp;أو الإحساس غير الطبيعي بالطعم،&nbsp;انخفاض&nbsp;إحساس الجلد&nbsp;بالألم واللمس،&nbsp;الإحساس&nbsp;بالوخز، الثقب، أو&nbsp;تنميل&nbsp;الجلد.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط حساسية&nbsp;العيون للضوء، جفاف العين، زيادة الدموع، احمرار العين.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإحساس بالدوار، طنين الأذن، ألم الأذن.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرجفان&nbsp;الأذيني&nbsp;(إيقاع قلب غير طبيعي)، انقطاع في التوصيل بين الجزأين العلوي والسفلي من القلب،&nbsp;خلل في التوصيل الكهربي للقلب، وإطالة فترة&nbsp;الكيو&nbsp;تي لقلبك، وبطء معدل ضربات القلب،&nbsp;خلل في الصورة الكهربائية للقلب&nbsp;(رسم القلب أو تخطيط القلب)،&nbsp;الشعور بخفقان&nbsp;أو&nbsp;دق شديد في&nbsp;صدرك (خفقان القلب).&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم، وانخفاض ضغط الدم عند&nbsp;الوقوف (ونتيجة لذلك، بعض الأشخاص الذين يتناولون&nbsp;ريسيدرا&nbsp;قد يشعرون بالدوار، والاغماء، أو قد&nbsp;يصابوا بفقدان الوعي&nbsp;عند الوقوف أو الجلوس فجأة،&nbsp;التوهج).&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الالتهاب الرئوي الناجم عن استنشاق الغذاء واحتقان الرئة، احتقان&nbsp;ممرات&nbsp;التنفس، أصوات&nbsp;طقطقة في&nbsp;الرئة،&nbsp;صفير، اضطراب الصوت، واضطراب&nbsp;في ممر&nbsp;التنفس.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب&nbsp;المعدة أو&nbsp;الأمعاء،&nbsp;سلس&nbsp;البراز،&nbsp;الصلابة الشديدة للبراز، وصعوبة البلع، والخروج&nbsp;المفرط للغازات أو الريح.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشرى&nbsp;(أو &quot;حمي&nbsp;قراصية&quot;)، الحكة، تساقط الشعر، سماكة الجلد، الاكزيما، والجلد الجاف، تلون الجلد، حب الشباب،&nbsp;تقشر، وحكة فروة الرأس أو الجلد،&nbsp;مشاكل&nbsp;الجلد،&nbsp;الآفة&nbsp;الجلدية.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة&nbsp;معدلات الكرياتين&nbsp;فوسفوكيناز&nbsp;في الدم،&nbsp;وهو&nbsp;إنزيم&nbsp;يصدر&nbsp;في بعض الأحيان مع انهيار العضلات.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وضع للجسم غير طبيعي، تصلب المفاصل، تورم&nbsp;المفاصل، وضعف العضلات، وألام الرقبة.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة معدلات التبول، وعدم القدرة على التبول والألم عند التبول.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف الانتصاب، اضطراب القذف.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان فترات الحيض، وغياب فترات الدورة الشهرية&nbsp;أو مشاكل أخرى&nbsp;خاصة بالدورة الشهرية لديك&nbsp;(بالنسبة للإناث).&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نمو حجم&nbsp;الثدي في الرجال، وتسرب الحليب من الثدي، العجز الجنسي، ألم الثدي، والشعور بعدم الراحة في&nbsp;الثدي،&nbsp;افرازات مهبلية.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم في الوجه، والفم، والعيون، أو الشفاه.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قشعريرة، زيادة في درجة حرارة الجسم.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ظهور&nbsp;تغيير في الطريقة التي كنت&nbsp;تمشي بها.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالعطش، الشعور بالإعياء،&nbsp;عدم الشعور بالراحة في&nbsp;الصدر،&nbsp;الإحساس&nbsp;&quot;منحرف المزاج&quot;، عدم الراحة&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة&nbsp;معدلات&nbsp;انزيمات الترانساميناز&nbsp;الكبدية&nbsp;في الدم،&nbsp;زيادة معدلات انزيم سي جي تي (إنزيم&nbsp;كبدي&nbsp;يسمى جاما&nbsp;جلوتاميل&nbsp;ترانسفيراز) في الدم، زيادة&nbsp;معدلات إنزيمات&nbsp;الكبد في الدم.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم العملية.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة&nbsp;(قد تؤثر&nbsp;على ما يصل إلى&nbsp;1 في 1,000 شخص):</strong>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إفراز غير ملائم للهرمون الذي يتحكم في حجم البول.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سكر في البول، وانخفاض نسبة السكر في الدم، ارتفاع&nbsp;نسبة الدهون الثلاثية في الدم&nbsp;(الدهون).&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص العاطفة، وعدم القدرة على الوصول إلى&nbsp;نشوة&nbsp;الجماع.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة الذهان الخبيثة (الارتباك، انخفاض أو فقدان الوعي، وارتفاع في&nbsp;درجة الحرارة وتصلب العضلات الحاد وتعرق).&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل الأوعية الدموية في المخ.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غيبوبة بسبب مرض السكري غير المنضبط.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اهتزاز&nbsp;الرأس.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المياه&nbsp;الزرقاء على العين&nbsp;(زيادة الضغط داخل مقلة العين)، والمشاكل المتعلقة بحركة عينيك،&nbsp;دوران حركة&nbsp;العين،&nbsp;تقشر حواف الجفن.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في العين أثناء جراحة&nbsp;إعتام عدسة العين.&nbsp; أثناء جراحة&nbsp;إعتام عدسة العين، من الممكن حدوث حالة تسمى متلازمة القزحية&nbsp;المرنة الموضعية (آى&nbsp;إف&nbsp;آي&nbsp;إس)&nbsp;إذا&nbsp;كنت تتناول أو تناولت مسبقا&nbsp;ريسيدرا.&nbsp;إذا كنت بحاجة إلى عملية جراحية&nbsp;لعلاج&nbsp;إعتام عدسة العين، يجب&nbsp;عليك&nbsp;التأكد من&nbsp;اخبار&nbsp;طبيب العيون الخاص بك إذا كنت&nbsp;تتناول أو تناولت مسبقا&nbsp;هذا الدواء.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض أعداد&nbsp;نوع معين من خلايا الدم البيضاء اللازمة لمكافحة العدوى في الدم&nbsp;علي نحو خطير.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد فعل&nbsp;تحسسي&nbsp;شديد&nbsp;يتميز بالحمى وتورم الفم والوجه، والشفة أو اللسان، ضيق في التنفس، وحكة، طفح الجلد وأحيانا انخفاض في ضغط الدم.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإفراط في تناول المياه&nbsp;بشكل خطير.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم انتظام ضربات القلب.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجلط الدم في الساقين، وتجلط الدم في الرئتين.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التنفس أثناء النوم (توقف التنفس أثناء النوم)،&nbsp;تنفس&nbsp;سريع&nbsp;وضحل.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس، انسداد في الأمعاء.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم اللسان،&nbsp;تشقق&nbsp;الشفاه،&nbsp;طفح على الجلد ذات صلة بالدواء.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القشرة.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تكسير&nbsp;ألياف العضلات وألام في العضلات&nbsp;(انحلال&nbsp;الربيدات).&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تأخير في فترات الطمث، توسيع الغدد في&nbsp;ثدييك، تكبير الثدي،&nbsp;ظهور افرازات من الثديين.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة&nbsp;الإنسولين&nbsp;(الهرمون الذي يتحكم في مستويات السكر في الدم) في الدم.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قُسَاح&nbsp;(انتصاب القضيب لفترات طويلة&nbsp;والذي&nbsp;قد&nbsp;يتطلب العلاج الجراحي).&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تصلب الجلد.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض درجة الحرارة&nbsp;الجسم&nbsp;وبرودة في الذراعين والساقين.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض انسحاب&nbsp;الدواء.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار في الجلد والعينين (اليرقان).&nbsp;</p><ul><li dir="RTL">المشي أثناء النوم</li><li dir="RTL">اضطرابات الأكل المرتبطة بالنوم</li><li dir="RTL">عدم التحرك أو الاستجابة أثناء الاستيقاظ.</li><li dir="RTL">الإفراط بشكل خطير في تناول المياه.&nbsp;</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة&nbsp;جداً (قد&nbsp;تؤثر على&nbsp;ما&nbsp;يصل إلى 1 في 10,000&nbsp;شخص):</strong>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضاعفات مرض السكري غير المنضبط&nbsp;المهددة للحياة.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ردود فعل تحسسية خطيرة&nbsp;مع تورم قد&nbsp;يشمل&nbsp;الحلق ويؤدي إلى صعوبة في التنفس.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف&nbsp;حركة&nbsp;عضلات&nbsp;الأمعاء&nbsp;مما&nbsp;يسبب انسداد.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">وقد&nbsp;لوحظ&nbsp;العرض&nbsp;الجانبي&nbsp;التالي&nbsp;أثناء&nbsp;استخدام دواء آخر يسمى&nbsp;باليبيريدون&nbsp;المشابه&nbsp;جدا&nbsp;ل&nbsp;ريسبيريدون،&nbsp;لذا من المتوقع إمكانية حدوث هذا العرض&nbsp;مع&nbsp;ريسيدرا: سرعة ضربات القلب عند الوقوف.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أعراض&nbsp;جانبية إضافية في الأطفال والمراهقين</strong>&nbsp;</p><p dir="RTL">بشكل عام،&nbsp;من المتوقع أن تكون الأعراض&nbsp;الجانبية في الأطفال&nbsp;مماثلة لتلك التي لدى البالغين.&nbsp;</p><p dir="RTL">تم الإبلاغ عن الأعراض&nbsp;الجانبية التالية&nbsp;بشكل أكثر شيوعا&nbsp;في الأطفال والمراهقين (5 إلى 17 سنة)&nbsp;عن البالغين: الشعور بالنعاس،&nbsp;أو ضعف الانتباه، الإرهاق (التعب)، الصداع، زيادة الشهية، والتقيؤ، وأعراض نزلات البرد، واحتقان&nbsp;الأنف،&nbsp;ألام&nbsp;في البطن، الدوخة والسعال والحمى،&nbsp;الرعاش&nbsp;(الاهتزاز)، الإسهال والسلس البولي&nbsp;(عدم التحكم&nbsp;في&nbsp;البول).&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن&nbsp;الأعراض&nbsp;الجانبية</strong>&nbsp;</p><p>إذا&nbsp;ظهرت عليك أي&nbsp;أعراض&nbsp;جانبية، قم بالتحدث مع طبيبك أو الصيدلي أو الممرضة. ويشمل ذلك أي&nbsp;أعراض&nbsp;جانبية محتملة&nbsp;غير المُدرجة في هذه النشرة. يمكنك أيضا الإبلاغ عن الأعراض&nbsp;الجانبية مباشرة عبر المركز الوطني للتيقظ&nbsp;والسلامة الدوائية. يمكنك من خلال الإبلاغ عن الأعراض&nbsp;الجانبية أن تساعد في توفير المزيد من المعلومات</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ&nbsp;بعيداً عن متناول ونظر الأطفال.&nbsp;</p><p dir="RTL">لا تستعمل هذا الدواء بعد انتهاء تاريخ الصلاحية المدون على العبوة&nbsp;أو الزجاجة. وتاريخ&nbsp;الانتهاء&nbsp;يشير إلى أخر يوم&nbsp;في&nbsp;الشهر المذكور.&nbsp;</p><p dir="RTL">لا&nbsp;يحفظ&nbsp;في درجة حرارة&nbsp;أعلي&nbsp;من&nbsp;30&nbsp;درجة مئوية.&nbsp;</p><p dir="RTL">لا تقم بتبريده أو تجميده.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">بمجرد فتح الزجاجة، يجب&nbsp;أن يتم تجاهل أي جزء غير مستخدم&nbsp;من المحلول الفموي&nbsp;ريسيدرا&nbsp;بعد 3 أشهر.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب عدم التخلص من الأدوية في مياه المجاري أو قمامة المنزل. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجتها. لأن هذه الاعتبارات ستعمل على حماية البيئة.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">المادة الفعالة&nbsp;هي&nbsp;ريسبيريدون&nbsp;</p><p dir="RTL">يحتوي&nbsp;كل&nbsp;1&nbsp;مل&nbsp;من المحلول الفموي&nbsp;على&nbsp;1&nbsp;ملجم&nbsp;ريسبيريدون.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">المكونات الأخرى:&nbsp;</p><p dir="RTL">حمض&nbsp;الطرطريك، حمض البنزويك، هيدروكسيد الصوديوم&nbsp;بي بي،&nbsp;ماء مقطر بي بي.&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ريسيدرا&nbsp;محلول فموي&nbsp;يتم توفيره&nbsp;في زجاجة&nbsp;كهرمانية&nbsp;مع غطاء&nbsp;بلاستيكي&nbsp;لولبي&nbsp;مقاوم&nbsp;للطفل&nbsp;(سي آر سي) وحلقة دالة على علامات العبث وتحتوي على 100 مل&nbsp;من محلول&nbsp;عديم اللون، خالي من&nbsp;الأجسام&nbsp;الغريبة. &nbsp;</p><p dir="RTL">&nbsp;&nbsp;</p><p dir="RTL">يتم تعبئة زجاجة&nbsp;ريسيدرا&nbsp;100 مل في عبوة من الورق المقوي تحتوي&nbsp;على&nbsp;محقنة فموية 3 مل&nbsp;مدرجة&nbsp;بحيث يكون الحد&nbsp;الأدنى&nbsp;للحجم&nbsp;0.25 مل والحد&nbsp;الأقصى&nbsp;للحجم 3 مل. علامات&nbsp;التدريج&nbsp;0.25 مل (تساوي 0.25 ملجم من المحلول الفموي)&nbsp;تزيد لتصل إلى 3 مل (تساوي 3 ملجم من المحلول الفموي)&nbsp;مطبوعة&nbsp;على هذه&nbsp;المحقنة وملئم&nbsp;المحقنة.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الدوائية</strong>&nbsp;</p><p dir="RTL">مصنع الأدوية بالقصيم&nbsp;</p><p dir="RTL">الشركة السعودية للصناعات الدوائية والمستلزمات الطبية&nbsp;</p><p dir="RTL">المملكة العربية السعودية&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            یولیو 2021 .
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                RESEDRA 1 mg/ml oral solution
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                1 ml oral solution contains 1 mg of risperidone
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The oral solution is a colourless solution, free from foreign matter.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>RESEDRA is indicated for the treatment of schizophrenia.</p><p>RESEDRA is indicated for the treatment of moderate to severe manic episodes associated with bipolar disorders.</p><p>RESEDRA is indicated for the short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe Alzheimer&#39;s dementia unresponsive to non-pharmacological approaches and when there is a risk of harm to self or others.</p><p>RESEDRA is indicated for the short-term symptomatic treatment (up to 6 weeks) of persistent aggression in conduct disorder in children from the age of 5 years and adolescents with subaverage intellectual functioning or mental retardation diagnosed according to DSM-IV criteria, in whom the severity of aggressive or other disruptive behaviours require pharmacologic treatment. Pharmacological treatment should be an integral part of a more comprehensive treatment programme, including psychosocial and educational intervention. It is recommended that risperidone be prescribed by a specialist in child neurology and child and adolescent psychiatry or physicians well familiar with the treatment of conduct disorder of children and adolescents.</p><p>RESEDRA is indicated for the treatment of irritability associated with autistic disorder in<br />children and adolescents aged 5 to 16 years, including symptoms of aggression towards others,<br />deliberate self-injuriousness, temper tantrums, and quickly changing moods.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>&nbsp;</p><p><u>Schizophrenia</u></p><p>&nbsp;</p><p><em>Adults</em></p><p>&nbsp;</p><p>RESEDRA may be given once daily or twice daily.</p><p>Patients should start with 2 mg/day risperidone. The dosage may be increased on the second day to 4 mg. Subsequently, the dosage can be maintained unchanged, or further individualised, if needed. Most patients will benefit from daily doses between 4 and 6 mg. In some patients, a slower titration phase and a lower starting and maintenance dose may be appropriate.</p><p>Doses above 10 mg/day have not demonstrated superior efficacy to lower doses and may cause increased incidence of extrapyramidal symptoms. Safety of doses above 16 mg/day has not been evaluated, and are therefore not recommended.</p><p>&nbsp;</p><p><em>Elderly</em></p><p>&nbsp;</p><p>A starting dose of 0.5 mg twice daily is recommended. This dosage can be individually adjusted with 0.5 mg twice daily increments to 1 to 2 mg twice daily.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>&nbsp;</p><p>Risperidone is not recommended for use in children below age 18 with schizophrenia due to a lack of data on efficacy.</p><p>&nbsp;</p><p><u>Manic episodes in bipolar disorder</u></p><p>&nbsp;</p><p><em>Adults</em></p><p>&nbsp;</p><p>RESEDRA should be administered on a once daily schedule, starting with 2 mg risperidone. Dosage adjustments, if indicated, should occur at intervals of not less than 24 hours and in dosage increments of 1 mg per day. Risperidone can be administered in flexible doses over a range of 1 to 6 mg per day to optimize each patient&#39;s level of efficacy and tolerability. Daily doses over 6 mg risperidone have not been investigated in patients with manic episodes.</p><p>As with all symptomatic treatments, the continued use of RESEDRA must be evaluated and justified on an ongoing basis.</p><p>&nbsp;</p><p><em>Elderly</em></p><p>&nbsp;</p><p>A starting dose of 0.5 mg twice daily is recommended. This dosage can be individually adjusted with 0.5 mg twice daily increments to 1 to 2 mg twice daily. Since clinical experience in elderly is limited, caution should be exercised.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>&nbsp;</p><p>Risperidone is not recommended for use in children below age 18 with bipolar mania due to a lack of data on efficacy.</p><p>&nbsp;</p><p><u>Persistent aggression in patients with moderate to severe Alzheimer&#39;s dementia</u></p><p>A starting dose of 0.25 mg twice daily is recommended. This dosage can be individually adjusted by increments of 0.25 mg twice daily, not more frequently than every other day, if needed. The optimum dose is 0.5 mg twice daily for most patients. Some patients, however, may benefit from doses up to 1 mg twice daily.</p><p>RESEDRA should not be used more than 6 weeks in patients with persistent aggression in Alzheimer&#39;s dementia. During treatment, patients must be evaluated frequently and regularly, and the need for continuing treatment reassessed.</p><p>&nbsp;</p><p><u>Conduct disorder</u></p><p>&nbsp;</p><p><em>Children and adolescents from 5 to 18 years of age</em></p><p>&nbsp;</p><p>For subjects &ge;50 kg, a starting dose of 0.5 mg once daily is recommended. This dosage can be individually adjusted by increments of 0.5 mg once daily not more frequently than every other day, if needed. The optimum dose is 1 mg once daily for most patients. Some patients, however, may benefit from 0.5 mg once daily while others may require 1.5 mg once daily. For subjects &lt;50 kg, a starting dose of 0.25 mg once daily is recommended. This dosage can be individually adjusted by increments of 0.25 mg once daily not more frequently than every other day, if needed. The optimum dose is 0.5 mg once daily for most patients. Some patients, however, may benefit from 0.25 mg once daily while others may require 0.75 mg once daily.</p><p>As with all symptomatic treatments, the continued use of RESEDRA must be evaluated and justified on an ongoing basis.</p><p>RESEDRA is not recommended in children less than 5 years of age, as there is no experience in children less than 5 years of age with this disorder.</p><p>Irritability Associated with Autistic Disorder<br />Pediatrics (Children andAdolescents)<br />The dosage of RESEDRA should be individualized according to the response and tolerability<br />of the patient. The total daily dose of RISPERDAL&reg; can be administered once daily, or half<br />the<br />total daily dose can be administered twice daily.<br />For patients with body weight less than 20 kg, initiate dosing at 0.25 mg per day. For patients<br />with body weight greater than or equal to 20 kg, initiate dosing at 0.5 mg per day. After a<br />minimum of four days, the dose may be increased to the recommended dose of 0.5 mg per day<br />for patients less than 20 kg and 1.0 mg per day for patients greater than or equal to 20 kg.<br />Maintain this dose for a minimum of 14 days. In patients not achieving sufficient clinical<br />response, the dose may be increased at intervals of 2 weeks or greater, in increments of 0.25<br />mg per day for patients less than 20 kg, or increments of 0.5 mg per day for patients greater than or<br />equal to 20 kg. The effective dose range is 0.5 mg to 3 mg per day. No dosing data are<br />available<br />for children who weigh less than 15 kg.<br />Once sufficient clinical response has been achieved and maintained, consider gradually<br />lowering<br />the dose to achieve the optimal balance of efficacy and safety. The physician who elects to use<br />RESEDRA for extended periods should periodically re-evaluate the long-term risks and<br />benefits of the drug for the individual patient.<br />Patients experiencing persistent somnolence may benefit from a once-daily dose administered<br />at<br />bedtime or administering half the daily dose twice daily, or a reduction of the dose.</p><p>&nbsp;</p><p><u>Renal and hepatic impairment</u></p><p>&nbsp;</p><p>Patients with renal impairment have less ability to eliminate the active antipsychotic fraction than in adults with normal renal function. Patients with impaired hepatic function have increases in plasma concentration of the free fraction of risperidone.</p><p>Irrespective of the indication, starting and consecutive dosing should be halved, and dose titration should be slower for patients with renal or hepatic impairment.</p><p>RESEDRA should be used with caution in these groups of patients.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>RESEDRA is for oral use. Food does not affect the absorption of RESEDRA.</p><p>Upon discontinuation, gradual withdrawal is advised. Acute withdrawal symptoms, including nausea, vomiting, sweating, and insomnia have very rarely been described after abrupt cessation of high doses of antipsychotic medicines (see section 4.8). Recurrence of psychotic symptoms may also occur, and the emergence of involuntary movement disorders (such as akathisia, dystonia and dyskinesia) has been reported.</p><p>&nbsp;</p><p><em>Switching from other antipsychotics.</em></p><p>&nbsp;</p><p>When medically appropriate, gradual discontinuation of the previous treatment while RESEDRA therapy is initiated is recommended. Also, if medically appropriate, when switching patients from depot antipsychotics, initiate RESEDRA therapy in place of the next scheduled injection. The need for continuing existing anti-Parkinson medicines should be re-evaluated periodically.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Elderly patients with dementia</u></p><p>&nbsp;</p><p><em>Increased mortality in elderly people with dementia</em></p><p>&nbsp;</p><p>In a meta-analysis of 17 controlled trials of atypical antipsychotics, including RESEDRA, elderly patients with dementia treated with atypical antipsychotics have an increased mortality compared to placebo. In placebo-controlled trials with oral RESEDRA in this population, the incidence of mortality was 4.0% for RESEDRA-treated patients compared to 3.1% for placebo-treated patients. The odds ratio (95% exact confidence interval) was 1.21 (0.7, 2.1). The mean age (range) of patients who died was 86 years (range 67-100). Data from two large observational studies showed that elderly people with dementia who are treated with conventional antipsychotics are also at a small increased risk of death compared with those who are not treated. There are insufficient data to give a firm estimate of the precise magnitude of the risk and the cause of the increased risk is not known. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear.</p><p>&nbsp;</p><p><em>Concomitant use with furosemide</em></p><p>&nbsp;</p><p>In the RESEDRA placebo-controlled trials in elderly patients with dementia, a higher incidence of mortality was observed in patients treated with furosemide plus risperidone (7.3%; mean age 89 years, range 75-97) when compared to patients treated with risperidone alone (3.1%; mean age 84 years, range 70-96) or furosemide alone (4.1%; mean age 80 years, range 67-90). The increase in mortality in patients treated with furosemide plus risperidone was observed in two of the four clinical trials. Concomitant use of risperidone with other diuretics (mainly thiazide diuretics used in low dose) was not associated with similar findings.</p><p>No pathophysiological mechanism has been identified to explain this finding, and no consistent pattern for cause of death observed. Nevertheless, caution should be exercised and the risks and benefits of this combination or co-treatment with other potent diuretics should be considered prior to the decision to use. There was no increased incidence of mortality among patients taking other diuretics as concomitant treatment with risperidone. Irrespective of treatment, dehydration was an overall risk factor for mortality and should therefore be carefully avoided in elderly patients with dementia.</p><p>&nbsp;</p><p><u>Cerebrovascular Adverse Events (CVAE)</u></p><p>&nbsp;</p><p>An approximately 3-fold increased risk of cerebrovascular adverse events have been seen in randomised placebo controlled clinical trials in the dementia population with some atypical antipsychotics. The pooled data from six placebo-controlled studies with RESEDRA in mainly elderly patients (&gt;65 years of age) with dementia showed that CVAEs (serious and non-serious, combined) occurred in 3.3% (33/1009) of patients treated with risperidone and 1.2% (8/712) of patients treated with placebo. The odds ratio (95% exact confidence interval) was 2.96 (1.34, 7.50). The mechanism for this increased risk is not known. An increased risk cannot be excluded for other antipsychotics or other patient populations. RESEDRA should be used with caution in patients with risk factors for stroke.</p><p>The risk of CVAEs was significantly higher in patients with mixed or vascular type of dementia when compared to Alzheimer&#39;s dementia. Therefore, patients with other types of dementias than Alzheimer&#39;s should not be treated with risperidone.</p><p>Physicians are advised to assess the risks and benefits of the use of RESEDRA in elderly patients with dementia, taking into account risk predictors for stroke in the individual patient. Patients/caregivers should be cautioned to immediately report signs and symptoms of potential CVAEs such as sudden weakness or numbness in the face, arms or legs, and speech or vision problems. All treatment options should be considered without delay, including discontinuation of risperidone.</p><p>RESEDRA should only be used short term for persistent aggression in patients with moderate to severe Alzheimer&#39;s dementia to supplement non-pharmacological approaches which have had limited or no efficacy and when there is potential risk of harm to self or others.</p><p>Patients should be reassessed regularly, and the need for continuing treatment reassessed.</p><p>&nbsp;</p><p><u>Orthostatic hypotension</u></p><p>&nbsp;</p><p>Due to the alpha-blocking activity of risperidone, (orthostatic) hypotension can occur, especially during the initial dose-titration period. Clinically significant hypotension has been observed postmarketing with concomitant use of risperidone and antihypertensive treatment. RESEDRA should be used with caution in patients with known cardiovascular disease (e.g., heart failure, myocardial infarction, conduction abnormalities, dehydration, hypovolemia, or cerebrovascular disease), and the dosage should be gradually titrated as recommended (see section 4.2). A dose reduction should be considered if hypotension occurs.</p><p>&nbsp;</p><p><u>Leukopenia, neutropenia, and agranulocytosis</u></p><p>&nbsp;</p><p>Events of leucopenia, neutropenia and agranulocytosis have been reported with antipsychotic agents, including RESEDRA. Agranulocytosis has been reported very rarely (&lt; 1/10,000 patients) during post-marketing surveillance.</p><p>Patients with a history of a clinically significant low white blood cell count (WBC) or a drug-induced leukopenia/neutropenia should be monitored during the first few months of therapy and discontinuation of RESEDRA should be considered at the first sign of a clinically significant decline in WBC in the absence of other causative factors.</p><p>Patients with clinically significant neutropenia should be carefully monitored for fever or other symptoms or signs of infection and treated promptly if such symptoms or signs occur. Patients with severe neutropenia (absolute neutrophil count &lt; 1 X 10<sup>9</sup>/L) should discontinue RESEDRA and have their WBC followed until recovery.</p><p>&nbsp;</p><p><u>Tardive dyskinesia/extrapyramidal symptoms (TD/EPS)</u></p><p>&nbsp;</p><p>Medicines with dopamine receptor antagonistic properties have been associated with the induction of tardive dyskinesia characterised by rhythmical involuntary movements, predominantly of the tongue and/or face. The onset of extrapyramidal symptoms is a risk factor for tardive dyskinesia. If signs and symptoms of tardive dyskinesia appear, the discontinuation of all antipsychotics should be considered.</p><p>&nbsp;</p><p>Caution is warranted in patients receiving both psychostimulants (e.g. methylphenidate) and risperidone concomitantly, as extrapyramidal symptoms could emerge when adjusting one or both medications. Gradual withdrawal of stimulant treatment is recommended (see section 4.5).</p><p>&nbsp;</p><p><u>Neuroleptic malignant syndrome (NMS)</u></p><p>&nbsp;</p><p>Neuroleptic Malignant Syndrome, characterised by hyperthermia, muscle rigidity, autonomic instability, altered consciousness and elevated serum creatine phosphokinase levels has been reported to occur with antipsychotics. Additional signs may include myoglobinuria (rhabdomyolysis) and acute renal failure. In this event, all antipsychotics, including RESEDRA, should be discontinued.</p><p>&nbsp;</p><p><u>Parkinson&#39;s disease and dementia with Lewy bodies</u></p><p>&nbsp;</p><p>Physicians should weigh the risks versus the benefits when prescribing antipsychotics, including RESEDRA, to patients with Parkinson&#39;s Disease or Dementia with Lewy Bodies (DLB). Parkinson&#39;s Disease may worsen with risperidone. Both groups may be at increased risk of Neuroleptic Malignant Syndrome as well as having an increased sensitivity to antipsychotic medicinal products; these patients were excluded from clinical trials. Manifestation of this increased sensitivity can include confusion, obtundation, postural instability with frequent falls, in addition to extrapyramidal symptoms.</p><p>&nbsp;</p><p><u>Hyperglycaemia and diabetes mellitus</u></p><p>&nbsp;</p><p>Hyperglycaemia, diabetes mellitus, and exacerbation of pre-existing diabetes have been reported during treatment with RESEDRA. In some cases, a prior increase in body weight has been reported which may be a predisposing factor. Association with ketoacidosis has been reported very rarely and rarely with diabetic coma. Appropriate clinical monitoring is advisable in accordance with utilised antipsychotic guidelines. Patients treated with any atypical antipsychotic, including RESEDRA, should be monitored for symptoms of hyperglycaemia (such as polydipsia, polyuria, polyphagia and weakness) and patients with diabetes mellitus should be monitored regularly for worsening of glucose control.</p><p>&nbsp;</p><p><u>Weight gain</u></p><p>&nbsp;</p><p>Significant weight gain has been reported with RESEDRA use. Weight should be monitored regularly.</p><p>&nbsp;</p><p><u>Hyperprolactinaemia</u></p><p>&nbsp;</p><p>Hyperprolactinaemia is a common side-effect of treatment with RESEDRA. Evaluation of the prolactin plasma level is recommended in patients with evidence of possible prolactin-related side-effects (e.g. gynaecomastia, menstrual disorders, anovulation, fertility disorder, decreased libido, erectile dysfunction, and galactorrhea).</p><p>Tissue culture studies suggest that cell growth in human breast tumours may be stimulated by prolactin. Although no clear association with the administration of antipsychotics has so far been demonstrated in clinical and epidemiological studies, caution is recommended in patients with relevant medical history. RESEDRA should be used with caution in patients with pre-existing hyperprolactinaemia and in patients with possible prolactin-dependent tumours.</p><p>&nbsp;</p><p><u>QT prolongation</u></p><p>&nbsp;</p><p>QT prolongation has very rarely been reported postmarketing. As with other antipsychotics, caution should be exercised when risperidone is prescribed in patients with known cardiovascular disease, family history of QT prolongation, bradycardia, or electrolyte disturbances (hypokalaemia, hypomagnesaemia), as it may increase the risk of arrhythmogenic effects, and in concomitant use with medicines known to prolong the QT interval.</p><p>&nbsp;</p><p><u>Seizures</u></p><p>&nbsp;</p><p>RESEDRA should be used cautiously in patients with a history of seizures or other conditions that potentially lower the seizure threshold.</p><p>&nbsp;</p><p><u>Priapism</u></p><p>&nbsp;</p><p>Priapism may occur with RESEDRA treatment due to its alpha-adrenergic blocking effects.</p><p>&nbsp;</p><p><u>Body temperature regulation</u></p><p>&nbsp;</p><p>Disruption of the body&#39;s ability to reduce core body temperature has been attributed to antipsychotic medicines. Appropriate care is advised when prescribing RESEDRA to patients who will be experiencing conditions which may contribute to an elevation in core body temperature, e.g., exercising strenuously, exposure to extreme heat, receiving concomitant treatment with anticholinergic activity, or being subject to dehydration.</p><p>&nbsp;</p><p><u>Antiemetic effect</u></p><p>&nbsp;</p><p>An antiemetic effect was observed in preclinical studies with risperidone. This effect, if it occurs in humans, may mask the signs and symptoms of overdosage with certain medicines or of conditions such as intestinal obstruction, Reye&#39;s syndrome, and brain tumour.</p><p>&nbsp;</p><p><u>Renal and hepatic impairment</u></p><p>&nbsp;</p><p>Patients with renal impairment have less ability to eliminate the active antipsychotic fraction than adults with normal renal function. Patients with impaired hepatic function have increases in plasma concentration of the free fraction of risperidone (see section 4.2).</p><p>&nbsp;</p><p><u>Venous thromboembolism</u></p><p>&nbsp;</p><p>Cases of venous thromboembolism (VTE) have been reported with antipsychotic drugs. Since patients treated with antipsychotics often present with acquired risk factors for VTE, all possible risk factors for VTE should be identified before and during treatment with RESEDRA and preventative measures undertaken.</p><p>&nbsp;</p><p><u>Intraoperative Floppy Iris Syndrome</u></p><p>&nbsp;</p><p>Intraoperative Floppy Iris Syndrome (IFIS) has been observed during cataract surgery in patients treated with medicines with alpha1a-adrenergic antagonist effect, including RESEDRA (see Section 4.8).</p><p>IFIS may increase the risk of eye complications during and after the operation. Current or past use of medicines with alpha1a-adrenergic antagonist effect should be made known to the ophthalmic surgeon in advance of surgery. The potential benefit of stopping alpha1 blocking therapy prior to cataract surgery has not been established and must be weighed against the risk of stopping the antipsychotic therapy.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>Before risperidone is prescribed to a child or adolescent with conduct disorder they should be fully assessed for physical and social causes of the aggressive behaviour such as pain or inappropriate environmental demands.</p><p>The sedative effect of risperidone should be closely monitored in this population because of possible consequences on learning ability. A change in the time of administration of risperidone could improve the impact of the sedation on attention faculties of children and adolescents.</p><p>Risperidone was associated with mean increases in body weight and body mass index (BMI). Baseline weight measurement prior to treatment and regular weight monitoring are recommended. Changes in height in the long-term open-label extension studies were within expected age-appropriate norms. The effect of long-term risperidone treatment on sexual maturation and height has not been adequately studied.</p><p>Because of the potential effects of prolonged hyperprolactinemia on growth and sexual maturation in children and adolescents, regular clinical evaluation of endocrinological status should be considered, including measurements of height, weight, sexual maturation, monitoring of menstrual functioning, and other potential prolactin-related effects.</p><p>Results from a small post-marketing observational study showed that risperidone-exposed subjects between the ages of 8-16 years were on average approximately 3.0 to 4.8 cm taller than those who received other atypical anti-psychotic medications. This study was not adequate to determine whether exposure to risperidone had any impact on final adult height, or whether the result was due to a direct effect of risperidone on bone growth, or the effect of the underlying disease itself on bone growth, or the result of better control of the underlying disease with resulting increase in linear growth.</p><p>During treatment with risperidone regular examination for extrapyramidal symptoms and other movement disorders should also be conducted.</p><p>The oral solution contains benzoic acid (E 210). Increase in bilirubinaemia following its displacement from albumin may increase neonatal jaundice which may develop into kernicterus (non-conjugated bilirubin deposits in the brain tissue).</p><p>&nbsp;</p><p>For specific posology recommendations in children and adolescents see Section 4.2.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pharmacodynamic-related Interactions</u></p><p>&nbsp;</p><p><em>Drugs known to prolong the QT interval</em></p><p>&nbsp;</p><p>As with other antipsychotics, caution is advised when prescribing risperidone with medicinal products known to prolong the QT interval, such as antiarrhythmics (e.g., quinidine, dysopiramide, procainamide, propafenone, amiodarone, sotalol), tricyclic antidepressants (i.e., amitriptyline), tetracyclic antidepressants (i.e., maprotiline), some antihistamines, other antipsychotics, some antimalarials (i.e., quinine and mefloquine), and with medicines causing electrolyte imbalance (hypokalaemia, hypomagnesiaemia), bradycardia, or those which inhibit the hepatic metabolism of risperidone. This list is indicative and not exhaustive.</p><p>&nbsp;</p><p><em>Centrally-Acting Drugs and Alcohol</em></p><p>&nbsp;</p><p>Risperidone should be used with caution in combination with other centrally-acting substances notably including alcohol, opiates, antihistamines and benzodiazepines due to the increased risk of sedation.</p><p>&nbsp;</p><p><em>Levodopa and Dopamine Agonists</em></p><p>&nbsp;</p><p>RESEDRA may antagonise the effect of levodopa and other dopamine agonists. If this combination is deemed necessary, particularly in end-stage Parkinson&#39;s disease, the lowest effective dose of each treatment should be prescribed.</p><p>&nbsp;</p><p><em>Drugs with Hypotensive Effect</em></p><p>&nbsp;</p><p>Clinically significant hypotension has been observed postmarketing with concomitant use of risperidone and antihypertensive treatment.</p><p>&nbsp;</p><p><em>Paliperidone</em></p><p>&nbsp;</p><p>Concomitant use of oral RESEDRA with paliperidone is not recommended as paliperidone is the active metabolite of risperidone and the combination of the two may lead to additive active antipsychotic fraction exposure.</p><p>&nbsp;</p><p>Psychostimulants</p><p>&nbsp;</p><p>The combined use of psychostimulants (e.g. methylphenidate) with risperidone can lead to extrapyramidal symptoms upon change of either or both treatments (see section 4.4).</p><p>&nbsp;</p><p><u>Pharmacokinetic-related Interactions</u></p><p>&nbsp;</p><p>Food does not affect the absorption of RESEDRA.</p><p>Risperidone is mainly metabolized through CYP2D6, and to a lesser extent through CYP3A4. Both risperidone and its active metabolite 9-hydroxyrisperidone are substrates of P-glycoprotein (P-gp). Substances that modify CYP2D6 activity, or substances strongly inhibiting or inducing CYP3A4 and/or P-gp activity, may influence the pharmacokinetics of the risperidone active antipsychotic fraction.</p><p>&nbsp;</p><p><em>Strong CYP2D6 Inhibitors</em></p><p>&nbsp;</p><p>Co-administration of RESEDRA with a strong CYP2D6 inhibitor may increase the plasma concentrations of risperidone, but less so of the active antipsychotic fraction. Higher doses of a strong CYP2D6 inhibitor may elevate concentrations of the risperidone active antipsychotic fraction (e.g., paroxetine, see below). It is expected that other CYP 2D6 inhibitors, such as quinidine, may affect the plasma concentrations of risperidone in a similar way. When concomitant paroxetine, quinidine, or another strong CYP2D6 inhibitor, especially at higher doses, is initiated or discontinued, the physician should re-evaluate the dosing of RESEDRA.</p><p>&nbsp;</p><p><em>CYP3A4 and/or P-gp Inhibitors</em></p><p>&nbsp;</p><p>Co-administration of RESEDRA with a strong CYP3A4 and/or P-gp inhibitor may substantially elevate plasma concentrations of the risperidone active antipsychotic fraction. When concomitant itraconazole or another strong CYP3A4 and/or P-gp inhibitor is initiated or discontinued, the physician should re-evaluate the dosing of RESEDRA.</p><p>&nbsp;</p><p><em>CYP3A4 and/or P-gp Inducers</em></p><p>&nbsp;</p><p>Co-administration of RESEDRA with a strong CYP3A4 and/or P-gp inducer may decrease the plasma concentrations of the risperidone active antipsychotic fraction. When concomitant carbamazepine or another strong CYP3A4 and/or P-gp inducer is initiated or discontinued, the physician should re-evaluate the dosing of RESEDRA. CYP3A4 inducers exert their effect in a time-dependent manner, and may take at least 2 weeks to reach maximal effect after introduction. Conversely, on discontinuation, CYP3A4 induction may take at least 2 weeks to decline.</p><p>&nbsp;</p><p><em>Highly Protein-bound Drugs</em></p><p>&nbsp;</p><p>When RESEDRA is taken together with highly protein-bound drugs, there is no clinically relevant displacement of either drug from the plasma proteins.</p><p>When using concomitant medication, the corresponding label should be consulted for information on the route of metabolism and the possible need to adjust dosage.</p><p>&nbsp;</p><p><u>Paediatric Population</u></p><p>&nbsp;</p><p>Interaction studies have only been performed in adults. The relevance of the results from these studies in paediatric patients is unknown.</p><p>The combined use of psychostimulants (e.g., methylphenidate) with RESEDRA in children and adolescents did not alter the pharmacokinetics and efficacy of RESEDRA.</p><p>&nbsp;</p><p><u>Examples</u></p><p>&nbsp;</p><p>Examples of drugs that may potentially interact or that were shown not to interact with risperidone are listed below:</p><p>&nbsp;</p><p><u>Effect of other medicinal products on the pharmacokinetics of risperidone</u></p><p>&nbsp;</p><p>Antibacterials:</p><p>&nbsp;</p><p>&bull; Erythromycin, a moderate CYP3A4 inhibitor and P-gp inhibitor, does not change the pharmacokinetics of risperidone and the active antipsychotic fraction.</p><p>&bull; Rifampicin, a strong CYP3A4 inducer and a P-gp inducer, decreased the plasma concentrations of the active antipsychotic fraction.</p><p>Anticholinesterases:</p><p>&bull; Donepezil and galantamine, both CYP2D6 and CYP3A4 substrates, do not show a clinically relevant effect on the pharmacokinetics of risperidone and the active antipsychotic fraction.</p><p>Antiepileptics:</p><p>&bull; Carbamazepine, a strong CYP3A4 inducer and a P-gp inducer, has been shown to decrease the plasma concentrations of the active antipsychotic fraction of risperidone. Similar effects may be observed with e.g. phenytoin and phenobarbital which also induce CYP 3A4 hepatic enzyme, as well as P-glycoprotein.</p><p>&bull; Topiramate modestly reduced the bioavailability of risperidone, but not that of the active antipsychotic fraction. Therefore, this interaction is unlikely to be of clinical significance.</p><p>Antifungals:</p><p>&bull; Itraconazole, a strong CYP3A4 inhibitor and a P-gp inhibitor, at a dosage of 200 mg/day increased the plasma concentrations of the active antipsychotic fraction by about 70%, at risperidone doses of 2 to 8 mg/day.</p><p>&bull; Ketoconazole, a strong CYP3A4 inhibitor and a P-gp inhibitor, at a dosage of 200mg/day increased the plasma concentrations of risperidone and decreased the plasma concentrations of 9-hydroxyrisperidone.</p><p>&nbsp;</p><p>Antipsychotics:</p><p>&nbsp;</p><p>&bull; Phenothiazines may increase the plasma concentrations of risperidone but not those of the active antipsychotic fraction.</p><p>&nbsp;</p><p>Antivirals:</p><p>&nbsp;</p><p>&bull; Protease inhibitors: No formal study data are available; however, since ritonavir is a strong CYP3A4 inhibitor and a weak CYP2D6 inhibitor, ritonavir and ritonavir-boosted protease inhibitors potentially raise concentrations of the risperidone active antipsychotic fraction.</p><p>&nbsp;</p><p>Beta blockers:</p><p>&nbsp;</p><p>&bull; Some beta-blockers may increase the plasma concentrations of risperidone but not those of the active antipsychotic fraction.</p><p>&nbsp;</p><p>Calcium channel blockers:</p><p>&nbsp;</p><p>&bull; Verapamil, a moderate inhibitor of CYP3A4 and an inhibitor of P-gp, increases the plasma concentration of risperidone and the active antipsychotic fraction.</p><p>&nbsp;</p><p>Gastrointestinal drugs:</p><p>&nbsp;</p><p>&bull; H<sub>2</sub>-receptor antagonists: Cimetidine and ranitidine, both weak inhibitors of CYP2D6 and CYP3A4, increased the bioavailability of risperidone, but only marginally that of the active antipsychotic fraction.</p><p>&nbsp;</p><p>SSRIs and Tricyclic antidepressants:</p><p>&nbsp;</p><p>&bull; Fluoxetine, a strong CYP2D6 inhibitor, increases the plasma concentration of risperidone, but less so of the active antipsychotic fraction.</p><p>&bull; Paroxetine, a strong CYP2D6 inhibitor, increases the plasma concentrations of risperidone, but, at dosages up to 20 mg/day, less so of the active antipsychotic fraction. However, higher doses of paroxetine may elevate concentrations of the risperidone active antipsychotic fraction.</p><p>&bull; Tricyclic antidepressants may increase the plasma concentrations of risperidone but not those of the active antipsychotic fraction. Amitriptyline does not affect the pharmacokinetics of risperidone or the active antipsychotic fraction.</p><p>&bull; Sertraline, a weak inhibitor of CYP2D6, and fluvoxamine, a weak inhibitor of CYP3A4, at dosages up to 100 mg/day are not associated with clinically significant changes in concentrations of the risperidone active antipsychotic fraction. However, doses higher than 100 mg/day of sertraline or fluvoxamine may elevate concentrations of the risperidone active antipsychotic fraction.</p><p>&nbsp;</p><p><u>Effect of risperidone on the pharmacokinetics of other medicinal products</u></p><p>&nbsp;</p><p>Antiepileptics:</p><p>&nbsp;</p><p>&bull; Risperidone does not show a clinically relevant effect on the pharmacokinetics of valproate or topiramate.</p><p>&nbsp;</p><p>Antipsychotics:</p><p>&nbsp;</p><p>&bull; Aripiprazole, a CYP2D6 and CYP3A4 substrate: Risperidone tablets or injections did not affect the pharmacokinetics of the sum of aripiprazole and its active metabolite, dehydroaripiprazole.</p><p>&nbsp;</p><p>Digitalis glycosides:</p><p>&nbsp;</p><p>&bull; Risperidone does not show a clinically relevant effect on the pharmacokinetics of digoxin.</p><p>&nbsp;</p><p>Lithium:</p><p>&bull; Risperidone does not show a clinically relevant effect on the pharmacokinetics of lithium.</p><p>&nbsp;</p><p><u>Concomitant use of risperidone with furosemide</u></p><p>&nbsp;</p><p>&bull; See section 4.4 regarding increased mortality in elderly patients with dementia concomitantly receiving furosemide.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>&nbsp;</p><p>There are no adequate data from the use of risperidone in pregnant women. Risperidone was not teratogenic in animal studies but other types of reproductive toxicity were seen (see section 5.3). The potential risk for humans is unknown.</p><p>Neonates exposed to antipsychotics (including RESEDRA) during the third trimester of pregnancy are at risk of adverse reactions including extrapyramidal and/or withdrawal symptoms that may vary in severity and duration following delivery. There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, or feeding disorder. Consequently, newborns should be monitored carefully.</p><p>RESEDRA should not be used during pregnancy unless clearly necessary. If discontinuation during pregnancy is necessary, it should not be done abruptly.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>In animal studies, risperidone and 9-hydroxy-risperidone are excreted in the milk. It has been demonstrated that risperidone and 9-hydroxy-risperidone are also excreted in human breast milk in small quantities. There are no data available on adverse reactions in breast-feeding infants. Therefore, the advantage of breast-feeding should be weighed against the potential risks for the child.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>As with other drugs that antagonize dopamine D2 receptors, RESEDRA elevates prolactin level. Hyperprolactinemia may suppress hypothalamic GnRH, resulting in reduced pituitary gonadotropin secretion. This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients.</p><p>&nbsp;</p><p>There were no relevant effects observed in the non-clinical studies.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>RESEDRA can have minor or moderate influence on the ability to drive and use machines due to potential nervous system and visual effects (see section 4.8). Therefore, patients should be advised not to drive or operate machinery until their individual susceptibility is known</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most frequently reported adverse drug reactions (ADRs) (incidence &ge;10%) are: Parkinsonism, sedation/somnolence, headache and insomnia.</p><p>The ADRs that appeared to be dose-related included parkinsonism and akathisia.</p><p>The following are all the ADRs that were reported in clinical trials and postmarketing experience with risperidone by frequency category estimated from RESEDRA clinical trials. The following terms and frequencies are applied: very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1000) and very rare (&lt;1/10,000).</p><p>Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td colspan="5" style="vertical-align:top"><p><strong>Adverse Drug Reaction</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Frequency</strong></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p><strong>Very Common</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td><td style="vertical-align:top"><p><strong>Very Rare</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>pneumonia, bronchitis, upper respiratory tract infection, sinusitis, urinary tract infection, ear infection, influenza</p></td><td style="vertical-align:top"><p>respiratory tract infection, cystitis, eye infection, tonsillitis, onychomycosis, cellulitis localised infection, viral infection, acarodermatitis</p></td><td style="vertical-align:top"><p>infection</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>neutropenia, white blood cell count decreased, thrombocytopenia, anaemia, haematocrit decreased, eosinophil count increased</p></td><td style="vertical-align:top"><p>agranulocytosis<sup>c</sup></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>hypersensitivity</p></td><td style="vertical-align:top"><p>anaphylactic reaction<sup>c</sup></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Endocrine disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>hyperprolactinaemia<sup>&nbsp;a</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>inappropriate antidiuretic hormone secretion, glucose urine present</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>weight increased, increased appetite, decreased appetite</p></td><td style="vertical-align:top"><p>diabetes mellitus<sup>&nbsp;b</sup>, hyperglycaemia, polydipsia, weight decreased, anorexia, blood cholesterol increased</p></td><td style="vertical-align:top"><p>water intoxication<sup>c</sup>, hypoglycemia, hyperinsulinaemia<sup>c</sup>, blood triglycerides increased</p></td><td style="vertical-align:top"><p>diabetic ketoacidosis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top"><p>insomnia<sup>d</sup></p></td><td style="vertical-align:top"><p>sleep disorder, agitation, depression, anxiety</p></td><td style="vertical-align:top"><p>mania, confusional state, libido decreased, nervousness, nightmare</p></td><td style="vertical-align:top"><p>blunted affect, anorgasmia,<strong> </strong>catatonia, somnambulism, sleep-related eating disorder.</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>sedation/ somnolence, parkinsonism<sup>&nbsp;d</sup>, headache</p></td><td style="vertical-align:top"><p>akathisia<sup>d</sup>, dystonia<sup>d</sup>, dizziness, dyskinesia<sup>d</sup>, tremor</p></td><td style="vertical-align:top"><p>tardive dyskinesia, cerebral ischaemia, unresponsive to stimuli, loss of consciousness, depressed level of consciousness, convulsion<sup>d</sup>, syncope, psychomotor hyperactivity, balance disorder, coordination abnormal, dizziness postural, disturbance in attention, dysarthria, dysgeusia, hypoaesthesia, paraesthesia</p></td><td style="vertical-align:top"><p>neuroleptic malignant syndrome, cerebrovascular disorder, diabetic coma, head titubation</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Eye disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>vision blurred, conjunctivitis</p></td><td style="vertical-align:top"><p>photophobia, dry eye, lacrimation increased, ocular hyperaemia</p></td><td style="vertical-align:top"><p>glaucoma, eye movement disorder, eye rolling, eyelid margin crusting, floppy iris syndrome (intraoperative)<sup>c</sup></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Ear and labyrinth disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>vertigo, tinnitus, ear pain</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>tachycardia</p></td><td style="vertical-align:top"><p>atrial fibrillation, atrioventricular block, conduction disorder, electrocardiogram QT prolonged, bradycardia, electrocardiogram abnormal, palpitations</p></td><td style="vertical-align:top"><p>sinus arrhythmia</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>hypertension</p></td><td style="vertical-align:top"><p>hypotension, orthostatic hypotension, flushing</p></td><td style="vertical-align:top"><p>pulmonary embolism, venous thrombosis</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>dyspnoea, pharyngolaryngeal pain, cough, epistaxis, nasal congestion</p></td><td style="vertical-align:top"><p>pneumonia aspiration, pulmonary congestion, respiratory tract congestion, rales, wheezing, dysphonia, respiratory disorder</p></td><td style="vertical-align:top"><p>sleep apnoea syndrome, hyperventilation</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>abdominal pain, abdominal discomfort, vomiting, nausea, constipation, diarrhoea, dyspepsia, dry mouth, toothache</p></td><td style="vertical-align:top"><p>faecal incontinence, faecaloma, gastroenteritis, dysphagia, flatulence</p></td><td style="vertical-align:top"><p>pancreatitis, intestinal obstruction, swollen tongue, cheilitis</p></td><td style="vertical-align:top"><p>ileus</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>rash, erythema</p></td><td style="vertical-align:top"><p>urticaria, pruritus, alopecia, hyperkeratosis, eczema, dry skin, skin discolouration, acne, seborrhoeic dermatitis, skin disorder, skin lesion</p></td><td style="vertical-align:top"><p>drug eruption, dandruff</p></td><td style="vertical-align:top"><p>angioedema</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>muscle spasms, musculoskeletal pain, back pain, arthralgia</p></td><td style="vertical-align:top"><p>blood creatine phosphokinase increased, posture abnormal, joint stiffness, joint swelling muscular weakness, neck pain</p></td><td style="vertical-align:top"><p>rhabdomyolysis</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>urinary incontinence</p></td><td style="vertical-align:top"><p>pollakiuria, urinary retention, dysuria</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Pregnancy, puerperium, and neonatal conditions</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>drug withdrawal syndrome neonatal<sup>c</sup></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>erectile dysfunction, ejaculation disorder, amenorrhoea, menstrual disorder<sup>d</sup>, gynaecomastia, galactorrhoea, sexual dysfunction, breast pain, breast discomfort, vaginal discharge</p></td><td style="vertical-align:top"><p>priapism<sup>c</sup>, menstruation delayed, breast engorgement, breast enlargement, breast discharge</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>oedema<sup>d</sup>, pyrexia, chest pain, asthenia, fatigue, pain</p></td><td style="vertical-align:top"><p>face oedema, chills, body temperature increased, gait abnormal, thirst, chest discomfort, malaise, feeling abnormal, discomfort</p></td><td style="vertical-align:top"><p>hypothermia, body temperature decreased, peripheral coldness, drug withdrawal syndrome, induration<sup>c</sup></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>transaminases increased, gamma-glutamyltransferase increased, hepatic enzyme increased</p></td><td style="vertical-align:top"><p>jaundice</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Injury, poisoning and procedural complications</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>fall</p></td><td style="vertical-align:top"><p>procedural pain</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr></tbody></table><p><sup>a</sup>&nbsp;Hyperprolactinemia can in some cases lead to gynaecomastia, menstrual disturbances, amenorrhoea, anovulation, galactorrhea, fertility disorder, decreased libido, erectile dysfunction.</p><p><sup>b</sup>&nbsp;In placebo-controlled trials diabetes mellitus was reported in 0.18% in risperidone-treated subjects compared to a rate of 0.11% in placebo group. Overall incidence from all clinical trials was 0.43% in all risperidone-treated subjects.</p><p><sup>c</sup>&nbsp;Not observed in RESEDRA clinical studies but observed in post-marketing environment with risperidone.</p><p><sup>d</sup>&nbsp;Extrapyramidal disorder may occur: Parkinsonism (salivary hypersecretion, musculoskeletal stiffness, parkinsonism, drooling, cogwheel rigidity, bradykinesia, hypokinesia, masked facies, muscle tightness, akinesia, nuchal rigidity, muscle rigidity, parkinsonian gait, and glabellar reflex abnormal, parkinsonian rest tremor), akathisia (akathisia, restlessness, hyperkinesia, and restless leg syndrome), tremor, dyskinesia (dyskinesia, muscle twitching, choreoathetosis, athetosis, and myoclonus), dystonia.</p><p>Dystonia includes dystonia, hypertonia, torticollis, muscle contractions involuntary, muscle contracture, blepharospasm, oculogyration, tongue paralysis, facial spasm, laryngospasm, myotonia, opisthotonus, oropharyngeal spasm, pleurothotonus, tongue spasm, and trismus. It should be noted that a broader spectrum of symptoms are included, that do not necessarily have an extrapyramidal origin.&nbsp;<strong>Insomnia</strong>&nbsp;includes: initial insomnia, middle insomnia;&nbsp;<strong>Convulsion</strong>&nbsp;includes: Grand mal convulsion;&nbsp;<strong>Menstrual disorder</strong>&nbsp;includes: Menstruation irregular, oligomenorrhoea;&nbsp;<strong>Oedema</strong>&nbsp;includes: generalisedoedema, oedema peripheral, pitting oedema.</p><p>&nbsp;</p><p><u>Undesirable effects noted with paliperidone formulations</u></p><p>&nbsp;</p><p>Paliperidone is the active metabolite of risperidone, therefore, the adverse reaction profiles of these compounds (including both the oral and injectable formulations) are relevant to one another. In addition to the above adverse reactions, the following adverse reaction has been noted with the use of paliperidone products and can be expected to occur with RESEDRA.</p><p>&nbsp;</p><p><strong>Cardiac disorders:&nbsp;</strong>Postural orthostatic tachycardia syndrome</p><p>&nbsp;</p><p><em>Class effects</em></p><p>&nbsp;</p><p>As with other antipsychotics, very rare cases of QT prolongation have been reported postmarketing with risperidone. Other class-related cardiac effects reported with antipsychotics which prolong QT interval include ventricular arrhythmia, ventricular fibrillation, ventricular tachycardia, sudden death, cardiac arrest and Torsades de Pointes.</p><p>&nbsp;</p><p><em>Venous thromboembolism</em></p><p>&nbsp;</p><p>Cases of venous thromboembolism, including cases of pulmonary embolism and cases of deep vein thrombosis, have been reported with antipsychotic drugs (frequency unknown).</p><p>&nbsp;</p><p><em>Weight gain</em></p><p>&nbsp;</p><p>The proportions of RESEDRA and placebo-treated adult patients with schizophrenia meeting a weight gain criterion of &ge; 7% of body weight were compared in a pool of 6- to 8-week, placebo-controlled trials, revealing a statistically significantly greater incidence of weight gain for RESEDRA (18%) compared to placebo (9%). In a pool of placebo-controlled 3-week studies in adult patients with acute mania, the incidence of weight increase of &ge; 7% at endpoint was comparable in the RESEDRA (2.5%) and placebo (2.4%) groups, and was slightly higher in the active-control group (3.5%).</p><p>In a population of children and adolescents with conduct and other disruptive behaviour disorders, in long-term studies, weight increased by a mean of 7.3 kg after 12 months of treatment. The expected weight gain for normal children between 5-12 years of age is 3 to 5 kg per year. From 12-16 years of age, this magnitude of gaining 3 to 5 kg per year is maintained for girls, while boys gain approximately 5 kg per year.</p><p>&nbsp;</p><p><u>Additional information on special populations</u></p><p>&nbsp;</p><p>Adverse drug reactions that were reported with higher incidence in elderly patients with dementia or paediatric patients than in adult populations are described below:</p><p><em>Elderly patients with dementia</em></p><p>Transient ischaemic attack and cerebrovascular accident were ADRs reported in clinical trials with a frequency of 1.4% and 1.5%, respectively, in elderly patients with dementia. In addition, the following ADRs were reported with a frequency &ge;5% in elderly patients with dementia and with at least twice the frequency seen in other adult populations: urinary tract infection, peripheral oedema, lethargy, and cough.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>In general, type of adverse reactions in children is expected to be similar to those observed in adults.</p><p>The following ADRs were reported with a frequency &ge;5% in paediatric patients (5 to 17 years) and with at least twice the frequency seen in clinical trials in adults: somnolence/sedation, fatigue, headache, increased appetite, vomiting, upper respiratory tract infection, nasal congestion, abdominal pain, dizziness, cough, pyrexia, tremor, diarrhoea, and enuresis.</p><p>The effect of long-term risperidone treatment on sexual maturation and height has not been adequately studied (see 4.4, subsection &ldquo;Paediatric population&rdquo;).</p><p>&nbsp;</p><p>Reporting of suspected adverse reactions</p><p>Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><p>To report any side effect(s):<br /> The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222, Exts: 2317-2356-2340.<br />o Hotline: 19999<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Symptoms</em></p><p>&nbsp;</p><p>In general, reported signs and symptoms have been those resulting from an exaggeration of the known pharmacological effects of risperidone. These include drowsiness and sedation, tachycardia and hypotension, and extrapyramidal symptoms. In overdose, QT-prolongation and convulsions have been reported. Torsade de Pointes has been reported in association with combined overdose of RESEDRA and paroxetine.</p><p>In case of acute overdose, the possibility of multiple drug involvement should be considered.</p><p>&nbsp;</p><p><em>Treatment</em></p><p>&nbsp;</p><p>Establish and maintain a clear airway and ensure adequate oxygenation and ventilation. Gastric lavage (after intubation, if the patient is unconscious) and administration of activated charcoal together with a laxative should be considered only when drug intake was less than one hour before. Cardiovascular monitoring should commence immediately and should include continuous electrocardiographic monitoring to detect possible arrhythmias.</p><p>There is no specific antidote to RESEDRA. Therefore, appropriate supportive measures should be instituted. Hypotension and circulatory collapse should be treated with appropriate measures such as intravenous fluids and/or sympathomimetic agents. In case of severe extrapyramidal symptoms, an anticholinergic medicinal product should be administered. Close medical supervision and monitoring should continue until the patient recovers.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Other antipsychotics, ATC code: N05AX08</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Risperidone is a selective monoaminergic antagonist with unique properties. It has a high affinity for serotoninergic 5-HT<sub>2</sub>and dopaminergic D<sub>2</sub>&nbsp;receptors. Risperidone binds also to alpha<sub>1</sub>-adrenergic receptors, and, with lower affinity, to H<sub>1</sub>-histaminergic and alpha<sub>2</sub>-adrenergic receptors. Risperidone has no affinity for cholinergic receptors. Although risperidone is a potent D<sub>2</sub>&nbsp;antagonist, which is considered to improve the positive symptoms of schizophrenia, it causes less depression of motor activity and induction of catalepsy than classical antipsychotics. Balanced central serotonin and dopamine antagonism may reduce extrapyramidal side effect liability and extend the therapeutic activity to the negative and affective symptoms of schizophrenia.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>&nbsp;</p><p><u>Clinical efficacy</u></p><p>&nbsp;</p><p><em>Schizophrenia</em></p><p>&nbsp;</p><p>The efficacy of risperidone in the short-term treatment of schizophrenia was established in four studies, 4- to 8-weeks in duration, which enrolled over 2500 patients who met DSM-IV criteria for schizophrenia. In a 6-week, placebo-controlled trial involving titration of risperidone in doses up to 10 mg/day administered twice daily, risperidone was superior to placebo on the Brief Psychiatric Rating Scale (BPRS) total score. In an 8-week, placebo-controlled trial involving four fixed doses of risperidone (2, 6, 10, and 16 mg/day, administered twice daily), all four risperidone groups were superior to placebo on the Positive and Negative Syndrome Scale (PANSS) total score. In an 8-week, dose comparison trial involving five fixed doses of risperidone (1, 4, 8, 12, and 16 mg/day administered twice-daily), the 4, 8, and 16 mg/day risperidone dose groups were superior to the 1 mg risperidone dose group on PANSS total score. In a 4-week, placebo-controlled dose comparison trial involving two fixed doses of risperidone (4 and 8 mg/day administered once daily), both risperidone dose groups were superior to placebo on several PANSS measures, including total PANSS and a response measure (&gt;20% reduction in PANSS total score). In a longer-term trial, adult outpatients predominantly meeting DSM-IV criteria for schizophrenia and who had been clinically stable for at least 4 weeks on an antipsychotic medicinal product were randomised to risperidone 2 to 8 mg/day or to haloperidol for 1 to 2 years of observation for relapse. Patients receiving risperidone experienced a significantly longer time to relapse over this time period compared to those receiving haloperidol.</p><p>&nbsp;</p><p><em>Manic episodes in bipolar disorder</em></p><p>&nbsp;</p><p>The efficacy of risperidone monotherapy in the acute treatment of manic episodes associated with bipolar I disorder was demonstrated in three double-blind, placebo-controlled monotherapy studies in approximately 820 patients who had bipolar I disorder, based on DSM-IV criteria. In the three studies, risperidone 1 to 6 mg/day (starting dose 3 mg in two studies and 2 mg in one study) was shown to be significantly superior to placebo on the pre-specified primary endpoint, i.e., the change from baseline in total Young Mania Rating Scale (YMRS) score at Week 3. Secondary efficacy outcomes were generally consistent with the primary outcome. The percentage of patients with a decrease of &ge; 50% in total YMRS score from baseline to the 3-week endpoint was significantly higher for risperidone than for placebo. One of the three studies included a haloperidol arm and a 9-week double-blind maintenance phase. Efficacy was maintained throughout the 9-week maintenance treatment period. Change from baseline in total YMRS showed continued improvement and was comparable between risperidone and haloperidol at Week 12.</p><p>The efficacy of risperidone in addition to mood stabilisers in the treatment of acute mania was demonstrated in one of two 3-week double-blind studies in approximately 300 patients who met the DSM-IV criteria for bipolar I disorder. In one 3-week study, risperidone 1 to 6 mg/day starting at 2 mg/day in addition to lithium or valproate was superior to lithium or valproate alone on the pre-specified primary endpoint, i.e., the change from baseline in YMRS total score at Week 3. In a second 3-week study, risperidone 1 to 6 mg/day starting at 2 mg/day, combined with lithium, valproate, or carbamazepine was not superior to lithium, valproate, or carbamazepine alone in the reduction of YMRS total score. A possible explanation for the failure of this study was induction of risperidone and 9-hydroxy-risperidone clearance by carbamazepine, leading to subtherapeutic levels of risperidone and 9-hydroxy-risperidone. When the carbamazepine group was excluded in a post-hoc analysis, risperidone combined with lithium or valproate was superior to lithium or valproate alone in the reduction of YMRS total score.</p><p>&nbsp;</p><p><em>Persistent aggression in dementia</em></p><p>&nbsp;</p><p>The efficacy of risperidone in the treatment of Behavioural and Psychological Symptoms of Dementia (BPSD), which includes behavioural disturbances, such as aggressiveness, agitation, psychosis, activity, and affective disturbances was demonstrated in three double-blind, placebo-controlled studies in 1150 elderly patients with moderate to severe dementia. One study included fixed risperidone doses of 0.5, 1, and 2 mg/day. Two flexible-dose studies included risperidone dose groups in the range of 0.5 to 4 mg/day and 0.5 to 2 mg/day, respectively. Risperidone showed statistically significant and clinically important effectiveness in treating aggression and less consistently in treating agitation and psychosis in elderly dementia patients (as measured by the Behavioural Pathology in Alzheimer&#39;s Disease Rating Scale [BEHAVE-AD] and the Cohen-Mansfield Agitation Inventory [CMAI]). The treatment effect of risperidone was independent of Mini-Mental State Examination (MMSE) score (and consequently of the severity of dementia); of sedative properties of risperidone; of the presence or absence of psychosis; and of the type of dementia, Alzheimer&#39;s, vascular, or mixed. (See also section 4.4)</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p><em>Conduct disorder</em></p><p>&nbsp;</p><p>The efficacy of risperidone in the short-term treatment of disruptive behaviours was demonstrated in two double-blind placebo-controlled studies in approximately 240 patients 5 to 12 years of age with a DSM-IV diagnosis of disruptive behaviour disorders (DBD) and borderline intellectual functioning or mild or moderate mental retardation/learning disorder. In the two studies, risperidone 0.02 to 0.06 mg/kg/day was significantly superior to placebo on the pre-specified primary endpoint, i.e., the change from baseline in the Conduct Problem subscale of the Nisonger-Child Behaviour Rating Form (N-CBRF) at Week 6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>RESEDRAorodispersible tablets and oral solution are bio-equivalent to RESEDRA film-coated tablets.</p><p>Risperidone is metabolised to 9-hydroxy-risperidone, which has a similar pharmacological activity to risperidone (see&nbsp;<em>Biotransformation and Elimination</em>).</p><p>&nbsp;</p><p><u>Absorption</u></p><p>&nbsp;</p><p>Risperidone is completely absorbed after oral administration, reaching peak plasma concentrations within 1 to 2 hours. The absolute oral bioavailability of risperidone is 70% (CV=25%). The relative oral bioavailability of risperidone from a tablet is 94% (CV=10%) compared with a solution. The absorption is not affected by food and thus risperidone can be given with or without meals. Steady-state of risperidone is reached within 1 day in most patients. Steady-state of 9-hydroxy-risperidone is reached within 4-5 days of dosing.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>&nbsp;</p><p>Risperidone is rapidly distributed. The volume of distribution is 1-2 l/kg. In plasma, risperidone is bound to albumin and alpha<sub>1</sub>-acid glycoprotein. The plasma protein binding of risperidone is 90%, that of 9-hydroxy-risperidone is 77%.</p><p>&nbsp;</p><p><u>Biotransformation and elimination</u></p><p>&nbsp;</p><p>Risperidone is metabolised by CYP 2D6 to 9-hydroxy-risperidone, which has a similar pharmacological activity as risperidone. Risperidone plus 9-hydroxy-risperidone form the active antipsychotic fraction. CYP 2D6 is subject to genetic polymorphism. Extensive CYP 2D6 metabolisers convert risperidone rapidly into 9-hydroxy-risperidone, whereas poor CYP 2D6 metabolisers convert it much more slowly. Although extensive metabolisers have lower risperidone and higher 9-hydroxy-risperidone concentrations than poor metabolisers, the pharmacokinetics of risperidone and 9-hydroxy-risperidone combined (i.e., the active antipsychotic fraction), after single and multiple doses, are similar in extensive and poor metabolisers of CYP 2D6.</p><p>Another metabolic pathway of risperidone is N-dealkylation.&nbsp;<em>In vitro</em>&nbsp;studies in human liver microsomes showed that risperidone at clinically relevant concentration does not substantially inhibit the metabolism of medicines metabolised by cytochrome P450 isozymes, including CYP 1A2, CYP 2A6, CYP 2C8/9/10, CYP 2D6, CYP 2E1, CYP 3A4, and CYP 3A5. One week after administration, 70% of the dose is excreted in the urine and 14% in the faeces. In urine, risperidone plus 9-hydroxy-risperidone represent 35-45% of the dose. The remainder is inactive metabolites. After oral administration to psychotic patients, risperidone is eliminated with a half-life of about 3 hours. The elimination half-life of 9-hydroxy-risperidone and of the active antipsychotic fraction is 24 hours.</p><p>&nbsp;</p><p><u>Linearity/non-linearity</u></p><p>&nbsp;</p><p>Risperidone plasma concentrations are dose-proportional within the therapeutic dose-range.</p><p>&nbsp;</p><p><u>Elderly, hepatic and renal impairment</u></p><p>&nbsp;</p><p>A single-dose PK-study with oral risperidone showed on average a 43% higher active antipsychotic fraction plasma concentrations, a 38% longer half-life and a reduced clearance of the active antipsychotic fraction by 30% in the elderly.</p><p>In adults with moderate renal disease the clearance of the active moiety was ~48% of the clearance in young healthy adults. In adults with severe renal disease the clearance of the active moiety was ~31% of the clearance in young healthy adults. The half-life of the active moiety was 16.7 h in young adults, 24.9 h in adults with moderate renal disease (or ~1.5 times as long as in young adults), and 28.8 h in those with severe renal disease (or ~1.7 times as long as in young adults). Risperidone plasma concentrations were normal in patients with liver insufficiency, but the mean free fraction of risperidone in plasma was increased by 37.1%.</p><p>The oral clearance and the elimination half-life of risperidone and of the active moiety in adults with moderate and severe liver impairment were not significantly different from those parameters in young healthy adults.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The pharmacokinetics of risperidone, 9-hydroxy-risperidone and the active antipsychotic fraction in children are similar to those in adults.</p><p>&nbsp;</p><p><u>Gender, race and smoking habits</u></p><p>&nbsp;</p><p>A population pharmacokinetic analysis revealed no apparent effect of gender, race or smoking habits on the pharmacokinetics of risperidone or the active antipsychotic fraction.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In (sub)chronic toxicity studies, in which dosing was started in sexually immature rats and dogs, dose-dependent effects were present in male and female genital tract and mammary gland. These effects were related to the increased serum prolactin levels, resulting from the dopamine D<sub>2</sub>-receptor blocking activity of risperidone. In addition, tissue culture studies suggest that cell growth in human breast tumours may be stimulated by prolactin. Risperidone was not teratogenic in rat and rabbit. In rat reproduction studies with risperidone, adverse effects were seen on mating behaviour of the parents, and on the birth weight and survival of the offspring. In rats, intrauterine exposure to risperidone was associated with cognitive deficits in adulthood. Other dopamine antagonists, when administered to pregnant animals, have caused negative effects on learning and motor development in the offspring. In a toxicity study in juvenile rats, increased pup mortality and a delay in physical development was observed. In a 40-week study with juvenile dogs, sexual maturation was delayed. Based on AUC, long bone growth was not affected in dogs at 3.6-times the maximum human exposure in adolescents (1.5 mg/day); while effects on long bones and sexual maturation were observed at 15 times the maximum human exposure in adolescents.</p><p>Risperidone was not genotoxic in a battery of tests. In oral carcinogenicity studies of risperidone in rats and mice, increases in pituitary gland adenomas (mouse), endocrine pancreas adenomas (rat), and mammary gland adenomas (both species) were seen. These tumours can be related to prolonged dopamine D<sub>2</sub>&nbsp;antagonism and hyperprolactinaemia. The relevance of these tumour findings in rodents in terms of human risk is unknown. In vitro and in vivo, animal models show that at high doses risperidone may cause QT interval prolongation, which has been associated with a theoretically increased risk of torsade de pointes in patients.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tartaric acid: 7.5 mg.</p><p>Benzoic acid: 2 mg.</p><p>Sodium hydroxide BP: 1 mg.</p><p>Purified water BP: q.s. to 1 mg</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Incompatible with most types of tea including black tea.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24Months/2 Years
Shelf life after first opening: 3 months

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C. Do not refrigerate or freeze.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>100ml amber glass bottle with white child-resistant plastic screw cap (CRC) and tamper-evident ring.</p><p>&nbsp;</p><p>The 100 ml glass bottle of Resedra &nbsp;is packed in a cardboard box containing a 3 ml oral syringe graduated with minimum 0.25 ml and a maximum of 3ml, graduation marks in 0.25 ml (equals 0.25 mg oral solution) increments up to 3 ml (equals 3 mg oral solution) are printed on the syringe and an adaptor for the syringe.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements for disposal</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SPIMACO
Al-Qassim Pharmaceutical Plant
Saudi Pharmaceutical Industries &
Medical Appliances Corporation.
Saudi Arabia

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                July 2021.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>